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SUMMARY (ENGLISH) 
Wild-type p53 plays an important role in the control of cellular metabolism, 
including glycolysis, mitochondrial oxidative phosphorylation, glutaminolysis, 
lipid metabolism, antioxidant defense and energy homeostasis. Mutation of the 
p53 gene is the most common genetic alteration among all human cancers. 
Prevalent p53 missense mutations abrogate its tumor suppressive function 
and lead to gain-of-function properties that promote cancer cell proliferation, 
chemoresistance, angiogenesis, migration, invasion, and metastasis. 
This doctoral thesis aims to identify the metabolic vulnerabilities of six p53 
hotspot mutants in lymphomas. In this work, three hotspot mutants, p53R245Q, 
p53R246S and p53R270H, were more sensitive to piperlongumine treatment in 
p53-deficient MEFs and Eμ-myc lymphoma cells than the empty control and 
the other three hotspot mutants, p53R172H, p53G242S and p53R279Q. Thereafter, I 
found piperlongumine-induced cell death was mediated by ROS accumulation 
via the activation of p38 and JNK. Antioxidant N-acetyl-L-cysteine (NAC) or 
p38/JNK inhibitors could completely or partially suppress 
piperlongumine-induced cell death. Upon piperlongumine treatment, p53R245Q, 
p53R246S and p53R270H-mutant inhibited piperlongumine-induced activation of 
p21 and consequently attenuated the activation and function of NRF2 induced 
by piperlongumine, contributing to the massive cell death in cells harboring 
these mutants. Similarly, KPT-330, a clinical inhibitor of Crm1, also caused 
severe cell death in p53-/- MEFs harboring p53R245Q, p53R246S and 
p53R270H-mutant. This implied that Crm1 could be also considered as a 
potential target for lymphomas harboring p53R245Q, p53R246S and 
p53R270H-mutant. 
Taken together, data presented in this work underscore the phenomenon that 
exogenous oxidative stress or Crm1 inhibitor is effective in eliminating cells 
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harboring p53R245Q, p53R246S and p53R270H-mutant with low toxicity to cells 
harboring the empty control, suggesting oxidative stress pathways or Crm1 as 
potential targets in lymphomas with p53R245Q, p53R246S and p53R270H-mutant. 
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ZUSAMMENFASSUNG 
Wildtyp p53 spielt eine wichtige Rolle in der Kontrolle des Zellmetabolismus, 
inklusive Glykolyse, mitochondriale oxidative Phosphorylierung, Glutaminolyse, 
Lipidmetabolismus, Abwehr gegen oxidativen Stress und Energiehomöostase. 
Mutation des p53 Gen ist die häufigste genetische Veränderung in allen 
humanen Tumoren. Weit verbreitete p53 misssense-Mutationen heben die 
Tumor suppressive Funktion auf und führen zu gain-of-function Eigenschaften, 
die Tumorproliferation, Chemoresistenz, Angiogenese, Migration, Invasion 
und Metastasen fördern. 
Diese Doktorarbeit soll die metabolischen Verwundbarkeiten von sechs p53 
Hotspot-Mutationen in Lymphomen identifizieren. In dieser Arbeit haben ich für 
drei solche Hotspot-Mutationen, p53R245Q, p53R246S und p53R270H, eine höhere 
Sensitivität gegenüber Behandlung mit Piperlongumine in p53-defizienten 
MEFs und Eµ-myc Lymphomzellen im Vergleich zur Kontrolle und den 
anderen drei Hotspot-Mutationen, p53R172H, p53G242S und p53R279Q, gefunden. 
Nachfolgend, haben ich entdeckt, dass Piperlongumine-induzierter Zelltod 
durch ROS Akkumulation über die Aktivierung von p38 und JNK, vermittelt 
wurde. Das Antioxidans N-acetyl-L-cysteine (NAC) oder p38/JNK Inhibitoren 
konnten vollständig oder teilweise Piperlongumine-induzierten Zelltod 
unterdrücken. Nach Behandlung mit Piperlongumine, haben  die p53R245Q, 
p53R246S und p53R270H-Mutanten die Aktivierung von p21 inhibiert und so die 
Aktivierung und Funktion von NRF2, durch Piperlongumine induziert, blockiert, 
dass zu dem massiven Zelltod in Zellen mit diesen Mutationen beiträgt. Auf 
ähnliche Weise, verursachte der klinisch verwendete Inhibitor von Crm1, 
KPT-330, schweren Zelltod in p53-/- MEFs mit den p53R245Q, p53R246S und 
p53R270H-Mutationen. Folglich könnte Crm1 als potenzielles Target für 
Lymphome mit p53R245Q, p53R246S und p53R270H-Mutationen berücksichtigt 
werden. 
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Zusammenfassend bekräftigen die Daten in dieser Arbeit das Phänomen, 
dass oxidativer Stress oder Crm1 Inhibitoren effektiv Zellen mit p53R245Q, 
p53R246S und p53R270H-Mutationen eliminieren können, mit niedriger Toxizität 
für Kontrollzellen. Demzufolge, könnten oxidativer Stress Signalwege oder 
Crm1 als potenzielle Angriffsziele für Lymphome mit p53R245Q, p53R246S und 
p53R270H-Mutationen dienen. 
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1 INTRODUCTION 
1.1 Discovery of p53 
p53 was originally discovered in complex with the large T-antigen of tumor 
virus Simian Virus 40 (SV-40) in 1979 by several research groups (Lane and 
Crawford, 1979; Linzer and Levine, 1979). In addition the p53 protein was also 
detected as a tumor antigen, eliciting an antibody response, when transformed 
mouse cells produced tumors in mice (DeLeo et al., 1979). In 1980s, many 
other groups also saw the isolation of several p53 cDNA clones and 
demonstrated that many of these cDNAs in combination with the Ras 
oncogene could transform cells (Eliyahu et al., 1985; Eliyahu et al., 1984; 
Parada et al., 1984). Thus p53 was initially established as an oncogene.  
However, by the end of 1980s, it became clear that each of these transforming 
cDNA clones contained a mutation and that the wild-type cDNA clone 
suppressed oncogenes mediated transformation of cells (Finlay et al., 1989). 
p53‟s new identity as a tumor suppressor was confirmed by other observations 
in 1990s. For instance, the cancer predisposition syndrome, Li-Fraumenni 
syndrome, occurring at an early age, was found to be due to germ-line 
mutation in p53 and subsequent loss of the wild-type p53 allele in tumor 
tissues (Malkin et al., 1990; Srivastava et al., 1990). p53 knockout mice, 
although appearing essentially normal, developed spontaneous tumors by 6 
months of age (Donehower et al., 1992). These observations revealed that the 
p53 protein plays a central role in preventing cancers in human and animals. 
 
1.2 Tumor suppression by p53 
As a transcription factor, p53 mainly exerts its function in tumor suppression 
through transcriptional regulation of its target genes (Elyada et al., 2011; 
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Kawamura et al., 2009; Kenzelmann Broz et al., 2013; Lujambio et al., 2013; 
Maddocks and Vousden, 2011; Yi et al., 2012). In response to diverse stress 
signals, including DNA damage, hypoxia, nutritional deprivation, oxidative 
stress and hyperproliferative signals (Figure 1), p53 is activated primarily 
through posttranslational modifications, which leads to the increase of p53 
protein half-life and therefore p53 protein accumulation in cells. The activated 
p53 protein then binds to a specific DNA sequence, which comprises two half 
sites of the nucleotide sequence RRRCWWGYYY (in which R = purine, W = A 
or T, and Y = pyrimidine), in its target genes to regulate their expression to 
start various cellular responses (Riley et al., 2008). Through these cellular 
responses, p53 facilitates DNA repair and inhibits the proliferation of cells that 
could potentially become cancerous. Regulating cell cycle arrest, senescence 
and apoptosis are most well-understood functions of p53, which are 
traditionally accepted as the main mechanisms for p53 in tumor suppression 
(Brady and Attardi, 2010; Vousden and Prives, 2009). Interestingly, recent 
studies have revealed that p53 regulates cellular energy metabolism (Bensaad 
et al., 2006; Feng and Levine, 2010; Matoba et al., 2006) and antioxidant 
defense (Budanov et al., 2004; Sablina et al., 2005), which contribute greatly 
to the role of p53 in tumor suppression. For instance, a recent study showed 
that while p53 deficiency results in the elevated intracellular reactive oxygen 
species (ROS) levels, DNA oxidation and mutations in cells, dietary 
supplementation with antioxidant Nacetylcysteine substantially improves 
karyotype stability and prevents the early-onset tumors in p53 null mice 
(Sablina et al., 2005). In another recent study, mice bearing lysine to arginine 
mutations at three (p533KR; K117R+K161R+K162R) of p53 acetylation sites 
were generated. p533KR/3KR cells display impaired p53-dependent cell-cycle 
arrest, senescence and apoptosis. Unlike p53 null mice, which rapidly 
succumb to lymphomas, p533KR/3KR mice did not develop early-onset 
lymphomas. Notably, p533KR/3KR cells retain the ability to regulate energy 
metabolism and ROS production (Li et al., 2012). These results strongly 
Introduction 
7 
suggest that uncanonical functions of p53, such as metabolic regulation and 
antioxidant function, could be critical for tumor suppression. 
 
Figure 1: Tumor suppressive functions of p53. p53 activation by a multitude of 
different stress signals, including nutrient deprivation, hypoxia, oxidative stress, 
hyperproliferative signals, DNA damage and ribonucleotide depletion, can 
consequently promote diverse responses of cell cycle arrest, senescence, apoptosis 
and DNA repair, leading to tumor suppression. Beyond triggering classical responses, 
p53 can modulate several additional cellular processes that are relevant to 
suppressing tumor development, including opposing oncogenic metabolic 
reprogramming and inhibiting the accumulation of reactive oxygen species (ROS), 
activating autophagy, promoting communication within the tumor microenvironment, 
suppressing stem cell self-renewal and reprogramming of differentiated cells into 
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stem cells, and preventing invasion and metastasis. Regulation of these processes by 
p53 may directly promote tumor suppression or may impinge on the canonical 
functions, such as apoptosis or senescence. Adapted from Bieging et al, 2014 
(Bieging et al., 2014). 
 
1.3 p53 in metabolic regulation 
Metabolic reprogramming, a hallmark of cancer cells, is characterized by the 
Warburg effect, in which high rates of glycolysis accompanied by reduced 
oxidative phosphorylation occur even under aerobic conditions (Gottlieb and 
Vousden, 2010; Maddocks and Vousden, 2011). To oppose this oncogenic 
metabolic reprogramming, p53 regulates mammalian target of rapamycin 
(mTOR) and AMP-activated protein kinase (AMPK), two master regulators of 
cellular metabolism, and directly influences various metabolic pathways 
(Gottlieb and Vousden, 2010; Liu et al., 2015; Maddocks and Vousden, 2011). 
Through the regulation of metabolic processes, p53 maintains the 
homeostasis of cellular metabolism and redox balance in cells, which 
contributes significantly to the role of p53 as a tumor suppressor. 
 
1.3.1 p53 and carbon metabolism 
Glucose is a major carbon source for mammalian cells. Once it is taken up by 
the cell, glucose is oxidized in the glycolytic pathway to pyruvate (in cytoplasm), 
which enters the tricarboxylic acid (TCA) cycle in mitochondria. Then it is 
further oxidized to produce NADH and FADH2, which carry electrons to the 
electron transport chain, in which ATP is produced through oxidative 
phosphorylation (OXPHOS).  
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1.3.1.1 Glucose metabolism 
Glucose is the major source for the generation of energy (ATP) and 
metabolites in various anabolic pathways (Tong et al., 2009; Vander Heiden et 
al., 2009). p53 plays a crucial role in regulating glucose metabolism. Several 
studies have found that p53 can limit glycolytic flux through multiple 
mechanisms. As shown in Figure 2, p53 negatively regulates glucose uptake 
through direct repression of the transcription of glucose transporter 1 and 4 
(Schwartzenberg-Bar-Yoseph et al., 2004), and indirect repression of the 
expression of GLUT3 (Kawauchi et al., 2008a, b). p53 down-regulates the 
protein level of phosphoglycerate mutase (PGM), a glycolytic enzyme, and 
inhibits glycolysis (Kondoh et al., 2005). p53 induces the expression of 
TP53-induced glycolysis and apoptosis regulator (TIGAR), which limits the 
activity of phosphofructokinase 1 (PFK1) and thus reduces glycolysis and 
diverts glycoltic intermediates into the pentose phosphate pathway (PPP) 
(Bensaad et al., 2006). p53 decreases the expression of pyruvate 
dehydrogenase kinase 2 (PDK2), which inactivates the pyruvate 
dehydrogenase complex that converts pyruvate to acetyl-CoA and inhibits 
lactate production (Contractor and Harris, 2012). p53 decrease the expression 
of monocarboxylate transporter 1 (MCT1) to inhibit lactate export produced by 
elevated glycolytic flux, and thereby prevents facilitation of the shift from 
mitochondrial oxidative phosphorylation to the glycolytic pathway (Boidot et al., 
2012). In addition, p53 induces the expression of Parkin, a gene associated 
with neurodegenerative Parkinson disease, to negatively regulate glycolysis 
(Zhang et al., 2011). 
PPP is an alternative pathway to glycolysis. Metabolites from glycolysis can be 
shunted into the PPP and used for the production of NADPH (an important 
intracellular reductant required for reductive biosynthesis) and ribose- 
5-phosphate (the precursor for biosynthesis of nucleotides) (Wamelink et al., 
2008). The glucose-6-phosphate dehydrogenase (G6PD) is the first and 
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rate-limiting enzyme of the PPP. p53 was reported to directly bind to G6PD 
and inhibit its activity, thereby inhibiting the diversion of glycolytic 
intermediates into the PPP (Jiang et al., 2011). Moreover, the overexpression 
of pyruvate kinase M2 (PKM2) in various types of tumors has been reported to 
associate with the activation of the PPP (Harris et al., 2012; Luo and Semenza, 
2012). PKM2 catalyzes phosphoenolpyruvate to pyruvate as the final step of 
glycolysis. PKM2 presents in an active tetrameric form in most normal 
proliferating cells, but in an inactive dimeric form in most tumors (Harris et al., 
2012; Luo and Semenza, 2012). Therefore, the overexpression of PKM2 in 
tumor cells inhibits glycolysis and leads to the shuttling of metabolic 
intermediates through the PPP (Harris et al., 2012; Luo and Semenza, 2012). 
 
1.3.1.2 Mitochondrial oxidative respiration 
Under normal aerobic conditions, the pyruvate produced by glycolysis can be 
fed into the TCA cycle as an efficient mechanism of ATP generation via 
OXPHOS (Figure 2). In coordination with repressing glycolysis, p53 also plays 
an important role in enhancing OXPHOS. p53 transcriptionally induces 
synthesis of cytochrome c oxidase 2 (SCO2), which regulates complex IV in 
the electron transport chain (Matoba et al., 2006), and apoptosis-inducing 
factor (AIF), which is required for mitochondrial complex I function (Stambolsky 
et al., 2006). In addition to inhibition of glycolysis, the induction of Parkin by 
p53 also stimulates OXPHOS. Parkin up-regulates the protein levels of 
pyruvate dehydrogenase E1 (PDHA1), which is an essential component of 
pyruvate dehydrogenase complex that catalyzes the conversion of pyruvate 
into acetyl-CoA for TCA cycle (Zhang et al., 2011). 
In addition, p53 involves in mitochondrial homeostasis by protecting 
mitochondrial DNA integrity and maintaining mitochondrial mass, through the 
activation of p53-controlled ribonucleotide reductase (p53R2) (Bourdon et al., 
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2007) and its interaction with mitochondrial DNA polymerase γ, which 
enhances DNA replication function of polymerase γ and therefore 
mitochondrial function (Achanta et al., 2005). 
 
1.3.1.3 Glutaminolysis 
Glutamine, which provides α-ketoglutarate (α-KG) into TCA cycle, is an 
alternative fuel to glucose for anabolic pathways. p53 induces the expression 
of mitochondrial glutaminase 2 (GLS2), which catalyzes the hydrolysis of 
glutamine to glutamate and further be converted into α-KG, and thereby 
promotes TCA cycle and OXPHOS (Hu et al., 2010; Suzuki et al., 2010). 
Furthermore, p53 inhibits the expression of malic enzymes ME1 and ME2. 
ME1 and ME2 recycle malate to pyruvate and provide intermediates for 
biosynthesis and NADPH production in TCA cycle (Jiang et al., 2013a). 
Therefore, through the inhibition of ME1 and ME2, p53 reduces the utilization 
of TCA cycle intermediates for biosynthesis and NADPH production to inhibit 
tumor cell proliferation. 
Introduction 
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Figure 2: Regulation of carbon metabolism by p53. p53 regulates metabolic 
pathways by modulating the transcription or activity of metabolic enzymes and by 
regulating signaling pathways that affect metabolic control. Proteins depicted in blue 
are up-regulated by p53, whereas proteins depicted in red are down-regulated by p53. 
p53 can suppress the transcription of glucose transporters GLUT1 and GLUT4 (and 
via NFКB inhibits GLUT3) to inhibit cellular glucose uptake. By transcriptional 
activation of TIGAR, p53 can suppress the rate of glycolysis and increase diversion of 
glycolytic intermediates into the PPP. p53 can also suppress glycolysis by promoting 
the degradation of PGM. The pentose phosphate pathway (PPP) can be inhibited by 
p53 through its binding to glucose-6-phosphate (G-6-P) dehydrogenase (G6PDH). 
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Furthermore, p53 promotes glutaminolysis to enhance the TCA cycle by activating 
GLS2 (converts glutamine to glutamate), while p53 negatively regulates the 
expression of ME1 and ME2 (enzymes involved in the TCA cycle). In addition, 
apoptosis-inducing factor (AIF) and synthesis of cytochrome c oxidase 2 (SCO2) are 
activated by p53 to promote oxidative phosphorylation (OXPHOS). Adapted from 
Jiang et al, 2013 (Jiang et al., 2013b). 
 
1.3.2 p53 and Lipid Metabolism 
Fatty acids are the major group of lipids that are used in cells. Fatty acids 
highly involve in energy storage, phospholipid membrane formation and 
signaling transduction. Fatty acid oxidation (FAO) and fatty acid synthesis 
(FAS) are the major aspects of lipid metabolism in cells. FAO takes place in 
the mitochondria and breaks down fatty acids into two-carbon units in order to 
yield acetyl-CoA, NADH, and FADH2, which can be used to drive the TCA 
cycle and generate the ATP needed to meet cellular energy demands. 
However FAS takes place in the cytosol and uses two-carbon units to form a 
gradually elongating carbon chain in a process that requires ATP and NADPH. 
Tumor cells frequently exhibit an increased rate of FAS, which can generate 
new phospholipid membrane to support the rapid growth and division of tumor 
cells (Mashima et al., 2009; Santos and Schulze, 2012). It has been reported 
that inhibition of FAS related enzymes leads to suppression of cell 
transformation and tumorigenesis, suggesting the important role of fatty acid 
synthesis in tumor development (Mashima et al., 2009; Santos and Schulze, 
2012). On the other hand, enhanced FAO can inhibit glycolysis and may 
contribute to tumor suppression (Goldstein and Rotter, 2012). 
Recent studies have shown that p53 plays a crucial role in regulation of lipid 
metabolism. As a tumor suppressor, p53 functions as a negative regulator of 
lipid synthesis by enhancing FAO and inhibiting FAS (Figure 3). For example, 
p53 can induce the expression of guanidinoacetate methyltransferase (GAMT), 
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carnitine O-palmitoyltransferase (CPT, such as CPT1C) and Lipin1 to enhance 
FAO (Assaily et al., 2011; Ide et al., 2009; Sanchez-Macedo et al., 2013; 
Zaugg et al., 2011). GAMT is a critical enzyme that synthesizes creatine, 
which plays an essential role in energy storage and transmission by 
re-synthesizing ATP (Ide et al., 2009; Zhu and Prives, 2009). In response to 
glucose starvation, GAMT is induced by p53 activation, which in turn 
up-regulates FAO (Ide et al., 2009). Carnitine acetyltransferases are 
responsible for the transport of fatty acids into the mitochondria for FAO 
(Sanchez-Macedo et al., 2013; Zaugg et al., 2011).  Metabolic stress factors 
such as hypoxia and glucose deprivation induce p53-dependent activation of 
CPT1C contributing to increase FAO and ATP production which protect cells 
from death (Sanchez-Macedo et al., 2013; Zaugg et al., 2011). As a nuclear 
transcriptional coactivator, Lipin1 induces the expression of genes involved in 
fatty acid oxidation through interaction with transcription factors PPARα and 
PGC-1α. p53 activates Lipin1 in response to glucose starvation, which in turn 
leads to the activation of fatty acid oxidation in cells (Assaily et al., 2011). 
Therefore, GAMT, CPT1C and Lipin1 connect p53 to FAO in response to 
nutritional stress.  
In addition to activating FAO, p53 also suppresses FAS. Transcription factor 
sterol regulatory element-binding protein 1 (SREBP1) activates the expression 
of enzymes involved in FAS, including fatty acid synthase (FASN), acetyl CoA 
carboxylase (ACC) and ATP citrate lyase (ACLY) (Yahagi et al., 2003). p53 
represses the expression of the SREBP1c isoform, contributing to the 
inhibition of FASN, ACC and ACLY (Yahagi et al., 2003). Moreover, the mTOR 
pathway and the PPP can promote fatty acid synthesis (Soliman, 2011; 
Wamelink et al., 2008). p53 has been reported to negatively regulate these two 
pathways, which leads to the repression of FAS (Feng and Levine, 2010; Jiang 
et al., 2011). 
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Figure 3: The regulation of lipid metabolism by p53. p53 generally functions as a 
negative regulator of lipid synthesis by enhancing fatty acid oxidation (pink) and 
inhibiting fatty acid synthesis (blue). p53 induces the expression of GAMT and CPT1C 
to enhance fatty acid oxidation, while suppresses the expression of SREBP1 
(contributing to the repression of FASN, ACC and ACLY) to inhibit fatty acid synthesis. 
In addition, activation of p53 induces Lipin1 (a negative regulator of SREBP), which 
also results in enhanced fatty acid oxidation. Adapted from Berkers et al, 2013 
(Berkers et al., 2013). 
 
1.3.3 p53 and the Regulation of ROS 
The regulation of carbohydrate and lipid metabolism by p53 is tightly linked to 
another important function of p53: the regulation of ROS. Oxidative stress and 
increased ROS levels of in cells play an important role in tumorigenesis. 
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Recent studies have shown that reducing the ROS levels and enhancing 
antioxidant defense is an important mechanism of p53 in tumor suppression 
(Berkers et al., 2013; Liang et al., 2013). To exert its antioxidant function, p53 
induces a variety of antioxidant genes, including TIGAR, GLS2, Sestrins 1/2, 
GPX1 and ALDH4, especially under conditions of non-stress or low stress, to 
lower ROS levels and prevent DNA damage (Figure 4) (Bensaad et al., 2006; 
Budanov et al., 2004; Hu et al., 2010; Tan et al., 1999; Yoon et al., 2004). 
TIGAR enhances antioxidant capacity of the cells by promoting the PPP and 
thereby increasing antioxidant NADPH levels (Bensaad et al., 2006). GLS2 
increases the intracellular levels of antioxidant glutathione (GSH), reducing 
ROS levels in cells (Hu et al., 2010). Sestrins are a family of proteins required 
for regeneration of peroxiredoxins, which are major reductants of peroxides in 
cells (Budanov et al., 2004). Glutathione peroxidase 1 (GPX1) is a primary 
antioxidant enzyme that scavenges hydrogen peroxide (H2O2) or 
hydroperoxides in cells (Tan et al., 1999). Aldehyde dehydrogenase 4 (ALDH4) 
is a NAD+ dependent enzyme in mitochondrial matrix, which catalyzes proline 
degradation and thus reduces ROS levels in cells (Yoon et al., 2004). In 
addition to the direct transcription regulation of antioxidant genes, p53 also 
reduces ROS levels by stabilizing NF-E2-related factor 2 (NRF2) through its 
up-regulation of p21 (Chen et al., 2009). As a transcription factor, NRF2 plays 
a crucial role in antioxidant defense through inducing several antioxidant 
genes. Under the conditions of nonstress, NRF2 is constantly ubiquitinated by 
the Cul3–Keap1 (Kelch-like ECH-associated protein 1) ubiquitin E3 ligase 
complex and rapidly degraded (Bryan et al., 2013). In response to oxidative 
stress, p53 up-regulates p21 and thereby inhibits the interaction between 
NRF2 and Keap1, leading to the stabilization of NRF2 (Chen et al., 2009). 
Interestingly, in addition to the function of antioxidant defense, p53 can exert 
pro-oxidant function through transcriptional regulation of a group of pro-oxidant 
genes depending on the levels of oxidative stress that cells are facing (Figure 
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4). In response to severe oxidative stress, the intracellular levels of ROS are 
elevated, leading to the p53-mediated apoptosis and senescence to eliminate 
cells damaged by oxidative stress. Meanwhile, the activated p53 induces the 
expression of pro-oxidant genes, including PIG3, PIG6, Bax, and PUMA, all of 
which can further induce ROS levels and promote the p53-mediated apoptosis 
and senescence to maintain genomic integrity (Bensaad and Vousden, 2007; 
Rivera and Maxwell, 2005). As mentioned above, p53 also can lower NADPH 
production by inactivation G6PDH and repressing the expression of ME1 and 
ME2. The inhibition of malic enzymes further activates p53 in a feed-forward 
manner by decreasing the levels of Mdm2 (Jiang et al., 2013a). The ability of 
p53 to limit and promote intracellular levels of ROS therefore contributes to its 
dual activities in controlling cell survival and cell death (Figure 4). 
 
Figure 4: The regulation of oxidative stress and ROS by p53. Under the 
conditions of nonstress (basal level of ROS, green stars) or low stress (excessive 
level of ROS, orange stars), p53 induces antioxidant genes, such as TIGAR, GLS2, 
Sestrins 1/2, GPX1, ALDH4, and NRF2 (p53 induces p21 to stabilize NRF2), to lower 
ROS levels in cells. This antioxidant activity protects cells from oxidative 
stress-induced DNA damage and mutations, and also promotes cell survival. Under 
the conditions of severe stress (orange stars), p53 induces pro-oxidant genes 
(including PIG3, PIG6, BAX and PUMA) or inhibits pro-oxidant genes (including 
G6PDH, ME1 and ME2), to further induce ROS levels in cells, which in turn further 
activates p53. This pro-oxidant activity leads to the p53-mediated apoptosis and 
senescence to prevent the propagation of mutation-bearing cells. Thus, both 
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antioxidant and pro-oxidant activities of p53 contribute to the role of p53 in tumor 
suppression. Adapted from Kruiswijk et al, 2015 (Kruiswijk et al., 2015). 
 
1.3.4 p53 and autophagy 
Autophagy (here referring to macroautophagy) is a highly conserved cellular 
catabolic process occurred in the cytoplasm. Autophagy is a membrane 
trafficking process that delivers long-lived proteins and aged or dysfunctional 
organelles to the lysosome for degradation (Xie and Klionsky, 2007). In the 
presence of sufficient external nutrients, autophagy acts as a homeostatic 
mechanism to maintain the integrity of protein and organelles in most 
situations. Under the condition of nutritional deprivation, autophagy can be 
activated to provide ATP from internal sources for cell survival. Recent studies 
have indicated that autophagy contributes to maintaining genomic stability and 
tumor prevention in normal cells, whereas autophagy might have two roles in 
tumor cells: either as a tumor-suppressive process by eliminating oncogenic 
protein substrates and damaged cells, or as a factor that promotes tumor 
progression by providing the materials needed for cell metabolism, growth, 
and proliferation (Kimmelman, 2011; Martinez-Outschoorn et al., 2017).  
p53 has been reported to promote autophagy through different mechanisms, 
which may lead to the role of p53 in tumor prevention. p53 promotes 
autophagy through negatively regulating mTOR, which is a major inhibitory 
regulator of autophagy. Furthermore, several p53 targets activate autophagy 
via mTOR-independent manner. Damage-regulated autophagy modulator 
(DRAM) is a lysosomal protein induced by p53 that positively regulates 
autophagy (Mah et al., 2012). Although DRAM does not induce cell death 
when overexpressed alone, it seems to be crucial for p53-mediated apoptosis 
and autophagy (Crighton et al., 2006; Maiuri et al., 2009). The pro-apoptotic 
p53 target BH3-containing proteins, including BAX, Bad, Bnip3 and PUMA, are 
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also believed to induce mitochondrial autophagy (mitophagy) by disrupting the 
inhibitory interaction between Beclin1 and Bcl-2/Bcl-X(L) (Maiuri et al., 2007; 
Yee et al., 2009; Zhang and Ney, 2009). Recently, the p53-inducible gene Ei24 
(also known as p53-induced gene 8) was found to be an essential component 
of the basal autophagy pathway in neurons and hepatocytes under 
nonstressed conditions (Zhao et al., 2012), suggesting that p53 may play a 
homeostatic role in promoting autophagy.  
In addition to promoting autophagy, p53 also inhibits this process under some 
circumstances. For example, cytoplasmic p53 was reported to repress 
autophagy through a transcription-independent effect exerted from a 
cytoplasmic localization in some cell lines (Tasdemir et al., 2008). Similarly, 
tumor-associated mutant p53 proteins, especially those located in the 
cytoplasm, were also reported to inhibit autophagy (Morselli et al., 2008). 
However, it is unclear whether cytoplasmic p53 and mutant p53 inhibit 
autophagy through different mechanisms. 
 
1.4 Mutant p53 gain-of-function in metabolism 
p53 is the most frequently mutated gene in human tumors. Unlike many other 
tumor suppressor genes, such as retinoblastoma-associated protein (RB), 
adenomatous polyposis coli (APC) and breast cancer type 1 susceptibility 
protein (BRCA1), which are predominantly inactivated during tumor 
progression through deletion or truncating mutations, majority of p53 mutations 
in human cancer are missense mutations (Freed-Pastor and Prives, 2012). 
About 74% of p53 mutations are missense mutations (Figure 5), which lead to 
the expression of full-length mutant p53 proteins with the substitution of a 
single amino acid. Although p53 mutations have been found in all coding 
exons of p53 gene, the majority of the missense mutations are clustered in 
exons 4~9, which is coding for p53 DNA-binding domain, resulting in the loss 
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of DNA-binding activity of mutant p53. Furthermore, about 30% of p53 
missense mutations frequently fall at six „hotspot‟ residues within the 
DNA-binding domain of p53 including residues R175, G245, R248, R249, 
R273 and R282 (Figure 5).  
 
Figure 5: Distribution of p53 somatic mutations according to the IARC p53 
mutation database. (A) Pie chart representing the different tumor-derived mutation 
types reported in the IARC p53 mutation database. (B) p53 missense mutation data 
for human patients (N = 24,320) were obtained from the IARC p53 mutation database. 
R175, G245, R248, R249, R273 and R282 are the six „hotspot‟ residues in p53. Data 
derived from the International Agency for Research on cancer (IARC) p53 mutation 
database version R18 (April 2016). 
 
74%
9%
8%
4% 3%
2%
Somatic mutations-mutations effect (N=28869)
IARC Tp53 datadase, R18, April 2016 
missense (73.16%)
Frameshift (9.06%)
Nonsense (8.17%)
Silent (3.62%)
Splice (2.4%)
Other (2.28%)
A
B
Introduction 
21 
p53 mutations have two major categories: DNA contact mutations (e.g. R248 
and R273) affecting residues involved directly in DNA contacts without altering 
p53 conformation, and conformational mutations (e.g. R175, G245, R249 and 
R282) that cause a conformational change in the core domain (Cho et al., 
1994; Freed-Pastor and Prives, 2012; Muller and Vousden, 2014). p53 
missense mutations are commonly loss-of-function mutations that loss of 
binding to p53 consensus DNA sequence in wild-type p53 target genes. In 
addition, these missense mutations are thought to have dominant-negative 
and/or gain-of-function properties (Freed-Pastor and Prives, 2012). 
Dominant-negative p53 mutants can bind and inactivate the product of 
remaining wild-type p53 gene allele and/or p63 and p73 proteins by formation 
of non-functioning tetrameric complexes, whereas gain-of-function mutants 
have additional oncogenic functions that are independent of wild-type p53 
(Freed-Pastor and Prives, 2012; Muller and Vousden, 2013). Many different 
gain-of-function properties of mutant p53 have been identified, including 
promoting cell proliferation, angiogenesis, migration, invasion, metastasis, and 
chemoresistance (Freed-Pastor and Prives, 2012; Muller and Vousden, 2013). 
For example, in vivo experiments have shown that mice harboring mutant p53 
display a more aggressive and metastatic tumor profile than p53 null or 
wild-type p53 mice (Doyle et al., 2010; Lang et al., 2004; Olive et al., 2004). 
The gain-of-function of mutant p53 has been clearly demonstrated in vitro by 
overexpression of mutant p53 in p53-null background or knockdown of 
endogenous mutant p53 in tumor cells that have lost the wild-type p53 allele 
(Freed-Pastor and Prives, 2012). Importantly, any experiments performed in 
cells that harbor wild-type p53 do not necessarily prove a gain-of-function, may 
simply reflect a dominant-negative effect (Bykov et al., 2002; Freed-Pastor and 
Prives, 2012). 
Recently, tumor-associated mutant p53 was reported to promote tumor 
metabolic changes as a novel gain-of-function in promoting tumor 
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development (Liu et al., 2015). For example, mutant p53 promotes tumor lipid 
metabolism. Mutant p53 (e.g. p53R273H and p53R280K) binds and activates 
transcription factor SREBPs, and thus induces the expression of many genes 
in the mevalonate pathway, a pathway that regulates lipid metabolism 
(Freed-Pastor et al., 2012). The activation of the mevalonate pathway by 
mutant p53 leads to the disruption of breast tissue architecture in 3D cell 
cultures, contributing to the mutant p53 gain-of-function in promoting breast 
tumorigenesis (Freed-Pastor et al., 2012). A recent study further showed that 
mutant p53 R172H promotes glycolysis and the Warburg effect as an additional 
novel gain-of-function of mutant p53 (Zhang et al., 2013). This gain-of-function 
activity of mutant p53 is mainly achieved through the activation of RhoA/ROCK 
signaling pathway, which in turn promotes the translocation of GLUT1 to the 
plasma membrane, and therefore promotes glucose uptake in tumor cells. 
Furthermore, melanoma cells expressing mutant p53R175H can utilize 
exogenous pyruvate to increase survival under the condition of glucose 
depletion (Chavez-Perez et al., 2011). Mutant p53 (including p53R175H, 
p53R248W, p53R249S, p53R273L and p53R280K) regulates nucleotide pools by 
transcriptionally up-regulating nucleotide biosynthesis pathways, thereby 
supporting cell proliferation and invasion (Kollareddy et al., 2015). In addition, 
mutant p53 has also been reported to involve in regulation of ROS by 
regulating NRF2. Mutant p53R273H attenuates the activation of NRF2 and 
further reduces the antioxidant response upon oxidative stress (Kalo et al., 
2012). While mutant p53 (e.g. p53H179Y and p53L194R) may confer cisplatin 
resistance via transcriptionally up-regulating Nrf2 expression in non-small cell 
lung cancer (NSCLC) (Tung et al., 2015). These findings together 
demonstrated an important role of mutant p53 in mediating tumor metabolic 
changes, providing a new mechanism underlying mutant p53 gain-of-function 
in tumorigenesis. 
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1.5 Mechanism of mutant p53 gain-of-function 
Recent studies have proposed the following several mechanisms by which 
mutant p53 gains novel oncogenic properties in tumor cells. 
 
Figure 6: Mechanisms of mutant p53 gain-of-function. There are several 
proposed mechanisms that contribute to different mutant p53 gain-of-function 
properties. These include both transcriptional and nontranscriptional mechanisms: (A) 
Mutant p53 interacts with p53 family members p63 and p73 to inhibit transactivation of 
their respective target genes. (B) Mutant p53 regulates transcription of genes by 
interacting with other cellular transcription factors. (C) Mutant p53 binds to DNA to 
regulate gene expression. (D) Mutant p53 interacts with other proteins that are not 
transcription factors, such as TopB1, Pin1, MRE11, PML, and others. (E) Mutant p53 
influences the expression and processing of miRNAs. Adapted from Liu et al, 2014 
(Liu et al., 2014a). 
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1.5.1 Mutant p53 interacts with p63 and p73 
p63 and p73 are two structural and functional homologs of p53 (Levrero et al., 
2000). In response to stress, p63 and p73 bind and activate many p53 target 
genes, and involve in a variety of important cellular processes, such as cell 
cycle arrest, apoptosis, and senescence. p63 and p73 were shown to form 
homotetramers and heterotetramers with each other, but neither p63 nor p73 
forms heterotetramers with wild-type p53 (Levrero et al., 2000). Interestingly, 
several mutant p53 were reported to interact with p63 and p73 to inhibit the 
transcriptional activities of p63 and p73. For instance, mutant p53R175H and 
p53R248W were found to interact with p63 and p73, whereas mutant p53R273H 
can only interact with p63 but not p73 (Di Como et al., 1999; Gaiddon et al., 
2001; Strano et al., 2002). The interaction between mutant p53 and p63/p73 
are associated with many oncogenic properties mediated by mutant p53, such 
as migration, metastasis and chemoresistance (Gaiddon et al., 2001; Li and 
Prives, 2007). 
 
1.5.2 Mutant p53 binds to transcription factors to regulate their function 
It has been reported that mutant p53 can interact with other transcription 
factors and be recruited to their binding sites to regulate the expression of their 
target genes. For example, mutant p53 interacted with nuclear factor Y (NF-Y) 
and induced the expression of NF-Y target genes (e.g. PLK2), which further 
phosphorylated mutant p53 and stimulated the binding of mutant p53 to p300 
(Di Agostino et al., 2006). Mutant p53 was also reported to bind to vitamin D 
receptor (VDR) and modulate the expression of VDR-regulated genes, 
augmenting the transactivation of some genes and relieving the repression of 
others (Stambolsky et al., 2010). Recently, mutant p53 was reported to interact 
with SREBP family members, SREBP-1a, SREBP-1c, and SREBP-2, and 
regulate the expression of genes in the mevalonate pathway to disrupt tissue 
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architecture in breast cancer cells (Freed-Pastor et al., 2012). In addition, 
mutant p53 has been showed to interact with NRF2, and attenuate the 
activation of NRF2 downstream genes upon oxidative stress (Kalo et al., 2012) 
or enhance transcription of numerous proteasome subunit genes (Walerych et 
al., 2016). 
 
1.5.3 Mutant p53 binds to DNA to alter gene expression 
Like wild-type p53 which primarily functions as a transcription factor, mutant 
p53 has been shown to modulate a number of genes involved in many different 
aspects of tumorigenesis (Brosh and Rotter, 2009; Strano et al., 2007; Weisz 
et al., 2007). Tumor-derived p53 mutants have been demonstrated to 
transactivate genes to promote proliferation of cancer cells, such as PCNA 
(Deb et al., 1992), myc (Frazier et al., 1998), and EGFR (Ludes-Meyers et al., 
1996), or to inhibit cell death, for instance, EGR1(Weisz et al., 2004), and 
NFKB2 (Vaughan et al., 2012). However, unlike wild-type p53, which is a DNA 
sequence-specific transcription factor, a consensus mutant-p53-specific DNA 
sequence has not been characterized so far.  
 
1.5.4 Mutant p53 interacts with proteins to change their function 
Mutant p53 can interact with some other proteins and affect their functions, 
which leads to the gain-of-function of mutant p53. For instance, mutant p53 
interacts with Mre11, a nuclear protein involved in homologous recombination 
and DNA repair, and thus promotes genomic instability and tumor progression 
(Song et al., 2007). In addition, mutant p53 interacts with promyelocytic 
leukemia (PML) protein, facilitating mutant p53 transcriptional activity (Haupt et 
al., 2009). Prolyl isomerase (Pin1), which regulates conformational changes of 
proteins to affect protein stability and activity, was reported to be an additional 
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mutant p53-binding protein. Pin1 enhances the oncogenic activity of mutant 
p53 to promote its pro-migration and invasion activities both by inhibition of 
p63 and by induction of a mutant p53 transcriptional program that correlates 
with poor clinical outcome in breast cancer (Girardini et al., 2011). 
 
1.5.5 Mutant p53 regulates miRNAs 
Recent studies also demonstrated that mutant p53 induces or represses the 
expression of certain microRNAs (miRNAs) to gain new oncogenic activities. 
For instance, mutant p53 exhibits oncogenic functions and promotes 
epithelial-mesenchymal transition (EMT) in endometrial cancer by directly 
binding to the promoter of miR-130b and inhibiting its transcription (Dong et al., 
2013). Mutant p53 activates the expression of miR-155 to drive invasion in 
breast cancer. MiR-155 inhibits the expression of zinc-finger transcriptional 
repressor ZNF652, which repressed the key drivers that promote invasion and 
metastasis (Neilsen et al., 2013). Moreover, mutant p53R273H binds to the 
miR-27a promoter region and suppresses its expression. Since EGFR is a 
direct target of miR-27a, mutant p53R273H promotes a continuous EGF-induced 
Erk1/2 activation through repressing miR-27a/EGFR axis, thereby facilitating 
cell proliferation and tumorigenesis (Wang et al., 2013).  
In addition to regulating the expression of miRNAs, mutant p53 also modulates 
the processing of miRNA. For example, mutant p53 inhibits the processing of 
primary miRNAs to precursor miRNAs through interfering assembly between 
Drosha complex and p68, leading to attenuation of the post-transcriptional 
maturation of several miRNAs in response to DNA damage, including 
miR-16-1, miR-143, and miR-145 (Suzuki et al., 2009).  
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1.6 Targeting mutant p53 for cancer therapy 
Increasing evidence reveals that stabilization of mutant p53 in tumors is crucial 
for its oncogenic activities, while depletion of mutant p53 attenuates malignant 
properties of cancer cells (Freed-Pastor and Prives, 2012; Gurpinar and 
Vousden, 2015; Muller and Vousden, 2013). Therefore, targeting mutant p53 
has become an attractive therapeutic strategy for cancer expressing mutant 
p53. The main strategies to target mutant p53 are restoring the wild-type p53 
activity and depleting mutant p53 in cancer. 
 
1.6.1 Restoring wild-type p53 activity 
Mutant p53 proteins stabilize and accumulate only in tumors but not in normal 
tissues as shown by mutant p53 knock-in mouse models (Alexandrova et al., 
2015; Lang et al., 2004). Therefore, restoring wild-type p53 activity can have 
the targeted effect on tumor cells containing mutant p53 while with limited side 
effects to normal tissues containing wild-type p53. Most p53 mutants lose their 
ability to bind with p53 consensus DNA sequence, thereby losing 
transcriptional activity and tumor suppressive function (Foster et al., 1999). A 
growing number of small molecules that can restore the lost wild-type function 
of mutant p53 proteins have been identified over the past two decades, such 
as PRIMA-1, APR-246 (PRIMA-1Met), NSC319726 (ZMC1), SCH529074, and 
PK7088 (Bykov et al., 2016). For example, PRIMA-1 efficiently induces 
apoptosis in p53-null Saos2 cells carrying p53R175H mutant in a mutant p53 
dependent manner (Bykov et al., 2002). PRIMA-1 and its methyl analog 
APR-246 can restore wild-type p53 activity by inducing conformation change 
of mutant p53 proteins and refolding accumulated unfolded mutant p53 
proteins (Bykov et al., 2002; Bykov et al., 2016). Importantly, PRIMA-1 is 
currently in phase I clinical trial, and APR-246 has entered a phase II clinical 
trial (Bykov et al., 2016). ZMC-1 (zinc metallochaperone-1) is another recently 
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identified small molecule that restores the proper protein folding and 
transcriptional activity of p53R175H mutant (Blanden et al., 2015). Zinc is 
essential for the proper folding of wild-type p53 protein to ensure 
sequence-specific DNA-binding activity of p53. ZMC-1 promotes the binding of 
mutant p53 to zinc, and thereby facilitates conformation change of mutant p53 
protein (Blanden et al., 2015). ZMC-1 only exhibited strong toxicity in p53R175H 
cells and a potent antitumor activity in p53R175H expressing tumors, but exerted 
limited effects in cells and tumors with other mutant p53 (p53R248Q and 
p53R273H) or wild-type p53 cells (Blanden et al., 2015). In addition, PK7088 
induces p53Y220C-dependent growth inhibition, cell cycle arrest and apoptosis 
by restoring wild-type p53 conformation in p53Y220C cells (Liu et al., 2013b). 
 
1.6.2 Depleting mutant p53 
Another approach to target oncogenic mutant p53 is to discover compounds 
that specifically deplete mutant p53 with little effect on wild-type p53. It has 
been reported that knockdown of mutant p53 by small interference RNAs 
(siRNAs) or short hairpin RNAs (shRNAs) markedly reduces malignant 
properties of cancer cells. For example, ablation of mutant p53 in a conditional 
inactivatable p53R248Q mouse model extends animal survival by 37% and 
induces tumor regression or stagnation (Alexandrova et al., 2015). These 
observations indicate that tumors containing mutant p53 depend on the 
presence of accumulated mutant p53 for continued growth, and strongly 
support depleting mutant p53 proteins as an effective therapeutic strategy for 
tumors with mutant p53. Recently, several compounds that induce mutant p53 
degradation without altering wild-type p53 have been found. 
Molecular chaperones, including heat shock protein 70 (Hsp70) and Hsp90, 
can inhibit the degradation of mutant p53 mediated by Hsp70-interacting 
protein (CHIP) (Li et al., 2011b; Muller et al., 2008). Inhibitors for Hsp90, 
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including geldanamycin, 17-AAG and Ganetespib, have been tested as 
therapeutic agents in cancer cells containing mutant p53. Treatment of cancer 
cells with 17-AAG promotes degradation of varieties of p53 mutants (including 
p53R175H, p53L194F, p53R273H and p53R280K) and decreases viability of cells 
containing these mutant p53 (Li et al., 2011b). Ganestespib, which has more 
than 50-fold higher efficacy than 17-AAG in destabilizing mutant p53 with little 
effect on wild-type p53 level, induces mutant p53 depletion with increased 
apoptosis both in p53R248Q HUPKI (humanized p53 knock-in) and p53R172H 
(equivalent to p53R175H in human) knock-in mouse models (Alexandrova et al., 
2015). Ganestespib is currently under evaluation in the clinical trial, including a 
phase III lung cancer trial (Goyal et al., 2015; Jhaveri et al., 2014; Ramalingam 
et al., 2015). In addition to Hsp90, inhibiting the activity of histone deacetylase 
6 (HDAC6), an essential positive regulator of Hsp90, has also been shown to 
degrade mutant p53 (p53R175H, p53R280K, and p53V274F/P223L) (Blagosklonny, 
2005; Li et al., 2011a). Histone deacetylase inhibitors (HDACi), specifically, 
suberoylanilide hydroxamic acid (SAHA), induce degradation of mutant p53 
protein by inhibiting HDAC6 activity, and subsequent disruption of the 
HDAC6/Hsp90/mutant p53 complex, leading to Mdm2 and CHIP mediated 
ubiquitination of mutant p53 protein (Li et al., 2011b; Marks, 2007). 
Furthermore, SAHA exhibits higher cytotoxic effects on cancer cells containing 
mutant p53 than those with wild-type p53 or deficient for p53 (Marks, 2007). 
Gambogic Acid (GA), a natural product from Garcinia hanburyi tree, has been 
shown to induce degradation of mutant p53 (p53R175H, p53G266E, p53R273H and 
p53R280K) by CHIP (Wang et al., 2011).  It has been revealed that GA prevents 
Hsp90/mutant p53 complex formation, enhances interaction of mutant p53 with 
Hsp70 and thus promotes degradation of mutant p53 (Wang et al., 2011). 
Arsenic trioxide (ATO), which is used to treat patient with acute promyelocytic 
leukemia (APL), binds to thiol groups in cysteine residues and induces 
proteasomal-dependent degradation of several p53 mutants (p53R175H, 
p53H179Y/R282W, p53R248W, and p53R273H) (Yan et al., 2014; Yan et al., 2011). 
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However, it should be noted that arsenic compounds have carcinogenic effects 
and are known to induce cancer, primarily of skin, bladder and lung (Hughes et 
al., 2011). Disulfiram (DSF), a strong ROS inducer, is used for the treatment of 
chronic alcoholism by inhibiting acetaldehyde dehydrogenase. It has been 
reported that DSF and its derivative copper-chelated disulfiram (CuDSF) 
induced proteasomal-dependent degradation of both wild-type p53 and mutant 
p53R273H (Paranjpe and Srivenugopal, 2013).  
In addition to target mutant p53 as cancer therapy strategy, reactivating tumor 
suppressive pathways that are inhibited by mutant p53 is also another way to 
target oncogenic activity of mutant p53. For example, reactivate transcriptional 
activity (RETRA) increases β-galactosidase activity and activates 
p53-regulated genes p21 and PUMA, thus specifically suppresses mutant p53 
(p53R248Q, p53R280L, and p53G266E) expressing tumor cells in vitro and in mouse 
xenografts (Kravchenko et al., 2008). 
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2 AIMS OF THE THESIS 
The tumor suppressor protein p53 plays a critical role in limiting malignant 
development and progression. Almost all cancers show loss of p53 function, 
through either mutation in the p53 gene itself or defects in the mechanisms 
that activate p53. Although reactivation of p53 can effectively limit tumor 
growth, this is a difficult therapeutic goal to achieve in many cancers that do 
not retain wild-type p53. An alternative approach focuses on identifying 
vulnerabilities imposed on cancers by virtue of the loss of or alterations in p53, 
to identify additional pathways that can be targeted to specifically kill or inhibit 
the growth of p53 mutated cells. 
In this work, by introducing the six p53 hotspot mutants into the same cell 
model in vitro to generate comparable system, we aim to figure out the specific 
metabolic phenotype owing to the gain-of-function properties of p53 mutants 
and further investigate the potential metabolic vulnerabilities which can be 
targeted for killing of cells harboring these p53 mutants. 
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Equipments 
Name Company 
Avanti J-26XP Ultra-Speed centrifuge Beckman Coulter 
Bioanalyzer 2100 Agilent Technologies 
Bacteria shaker Innova 4000 New Brunswick Scientific 
Cell culture dishes and falcons TPP 
Cell culture incubator Thermo Scientific 
Centrifuge Rotina 35R  Hettich 
Centrifuge 5417R Eppenorf 
ChemiDoc MP Imaging System Biorad 
Cryotubes  Sefar company 
FACS Calibur Becton Dickinson 
Guava easyCyte 8HT Benchtop Flow 
Cytometer 
Millipore 
Megafuge 1.0 R Eppendorf 
Microscopy Immersion Oil  Merck 
Microscope Zeiss Telaval 31 Zeiss 
Microwave Siemens 
Mr. Frosty Freezing Container Thermo Scientific 
NanoDrop ND-2000 Peqlab 
Pipettes Eppendorf 
pH-meter HI2211 Hanna Instruments 
Polystyrene tubes BD Falcon 
PVDF membrane (Immobilon-P) Millipore 
Rotilabo Filter sterile (0.45 μM PVDF) Carl Roth 
Scalpel for single-use Feather 
SDS-PAGE Chamber Carl Roth 
Seahorse XFe24 Analyzer Seahorse Bioscience 
Serological pipettes Falcon Becton Dickinson 
Semi-dry transfer system Biorad 
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StepOnePlus™ Real-Time PCR 
System 
Applied Biosystems 
Thermo-cycler PCR machine Peqlab 
Thermomixer Peqlab 
Whatman paper (3MM) Schleicher-Schuell 
XF24 cell culture microplates Seahorse Bioscience 
XF24 sensor cartridge Seahorse Bioscience 
 
3.1.2 Chemicals and reagents 
Name Company 
30% Acrylamide/Bis-acrylamide Carl Roth 
Agar Carl Roth 
Agarose Serva Electrophoresis 
Albumin Fraktion V Carl Roth 
Annexin V Sigma 
Ammoniumpersulfate (APS) Carl Roth 
Ampicillin sodium salt Carl Roth 
Antimycin A Sigma 
Bradford reagent (RotiQuant) Carl Roth 
Bromephenolblue powder Euro-bio 
Calciumchloride [CaCl2] Carl Roth 
Carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP) 
Sigma 
Chloroform Merck 
Crystal violet Sigma 
2-Deoxy-D-glucose (2-DG) Sigma 
2',7'-dichlorodihydrofluorescein diacetate 
[H2DCFDA] 
Invitrogen 
Diethyl pyrocarbonate (DEPC) Sigma 
diSodiumhydrogenphosphatedihydrate [Na2HPO4 
x 2H2O] 
Merck 
dNTPs Biochrom 
Dulbecco s´ MEM (DMEM) Life technologies 
DTT  Eurobio 
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ECL reagent Millipore 
Ethanol, absolute Carl Roth 
Ethylenediaminetetraacetate (EDTA) Carl Roth 
Fetal Calf Serum (FCS) Biochrom 
Formaldehyde  Carl Roth 
Glacial acetic acid Merck 
Glucose Carl Roth 
Glycerol Carl Roth 
Glycine Serva Electrophoresis 
HEPES Carl Roth 
Hexademethrinebromide (Polybrene)  Sigma 
Hydrochloric acid (HCl) Merck 
Hydrogen peroxide (H2O2) Sigma 
Iscove's modified Eagle's media (IMEM) Life technologies 
L-Glutamine (powder) Biochrom 
L-Glutamine (solution) Life technologies 
Magnesiumchloride for PCR Applied Biosystems 
Magnesiumchloride-hexahydrate [MgCl2]  Carl Roth 
β-Mercaptoethanol Carl Roth 
Methanol Carl Roth 
Milk powder Carl Roth 
N-acetyl-L-cysteine Sigma 
N,N,N ,´N -´Tetramethylethylenediamine (TEMED) Sigma 
N,N-dimethylsulfoxide (DMSO) Carl Roth 
Na-Desoxycholate Sigma 
Nonident 40 (NP-40) Merck 
PageRuler Plus Prestained Protein Ladder Thermo Scientific 
10 x PCR buffer Applied Biosystems 
Penicillin-streptomycin Biochrom 
Phosphate Buffered Saline (PBS) Carl Roth 
Piperlongumine (PL) Sigma 
Phenylmethylsulfonylfluoride (PMSF) Sigma 
Potassiumchloride (KCl) Merck 
Propidium iodide (PI) Sigma 
2-propanol Carl Roth 
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Protease inhibitors (Complete protease inhibitor 
mix) 
Roche 
Puromycin Calbiochem 
SB202190 Cell signaling Technology 
Sodiumchloride [NaCl] Merck 
Sodiumdodecylsufat (SDS) Carl Roth 
Sodiumfluoride [NaF] Sigma 
Sodiumhydroxide [NaOH] Carl Roth 
Sodiumorthovanadate Sigma 
SP600125 Cell signaling Technology 
Taq polymerase Applied Biosystems 
tert-Butyl hydroperoxide (tBHP) Sigma 
Tris(hydroxymethyl) base Sigma 
Triton X-100 Merck 
TRIZOL reagent Gibco Invitrogen 
Trypan blue solution Sigma 
Trypsin-EDTA Biochrom 
Tween 20 Carl Roth 
Seahorse XF base medium Seahorse Bioscience 
 
3.1.3 Enzymes 
Name Company 
Bgl II  NEB 
EcoR I  NEB 
Hind III NEB 
Xho I NEB 
Proteinase K Merck 
RNAse A Fluka 
RNAse-out RNAse Inhibitor  Invitrogen 
Superscript Reverse Transcriptase III Invitrogen 
T4 DNA ligase NEB 
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3.1.4 Antibodies 
Name Catalog number Company 
β-actin 4970 Cell signaling 
Technology 
Anti-mouse IgG 5415 Cell signaling 
Technology 
Cleaved caspase 3 
(Asp175) 
9661 Cell signaling 
Technology 
C-myc 9E10 Santa Cruz 
Biotechnology 
NRF2 (N2C2) GTX103322 GeneTex 
p21 (c-19) SC-397 Santa Cruz 
Biotechnology 
p21 (SXM30) 556431 BD Pharmingen 
p38 MAPK 9212 Cell signaling 
Technology 
p44/42 MAPK (Erk1/2) 9102 Cell signaling 
Technology 
p53 (Ab-1) OP03 Calbiochem 
p53 (CM5) NCL-p53-CM5p Novocastra 
SAPK/JNK Antibody  9252 Cell signaling 
Technology 
Phospho-p38 MAPK  
(Thr180/Tyr182) 
9211 Cell signaling 
Technology 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
9251 Cell signaling 
Technology 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204)  
9101 Cell signaling 
Technology 
α-Tubulin T-5168 Sigma 
Anti-rabbit IgG HRP NA9340 Amersham 
Anti-mouse IgG HRP NXA931 Amersham 
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3.1.5 Commercial kits 
Name Catalog 
Number 
Company 
BCA Protein Assay Kit 23225 Pierce 
CellROX Green Reagent C10444 Invitrogen 
Fast SYBR® Green Master Mix 4385612 Applied 
Biosystems 
Guava ViaCount Reagent for Flow 
Cytometry 
4000-0040 Millipore 
iDeal ChIP-seq kit for Transcription 
Factors 
C01010170 Diagenode 
M-PER™ Mammalian Protein 
Extraction Reagent 
78501 Pierce 
PureLink® HiPure Plasmid Filter 
Maxiprep Kit 
K2100-17 Invitrogen 
SuperScript® III First-Strand Synthesis 
System 
18080-051 Invitrogen 
TaqMan® Gene Expression Master 
Mix 
4369016 Applied 
Biosystems 
 
3.1.6 Bacteria 
DH5α E.coli Genotype: F´ proA+B+ lacIq ∆ lacZ M15/ fhuA2 ∆(lac-proAB) 
glnV gal R(zgb-210::Tn10)TetS endA1 thi-1 ∆(hsdS-mcrB)5 
 
3.1.7 Plasmids 
Name Backbone 
MSCV-myc-hygromycin MSCV-hygromycin 
MSCV-empty-puro MSCV-puro 
MSCV-wtp53-puro  MSCV-puro 
MSCV-p53-R172H-puro MSCV-puro 
MSCV-p53-G242S-puro MSCV-puro 
MSCV-p53-R245Q-puro MSCV-puro 
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MSCV-p53-R246S-puro MSCV-puro 
MSCV-p53-R270H-puro MSCV-puro 
MSCV-p53-R279Q-puro MSCV-puro 
 
3.1.8 Primers 
Name Sequences 
Cloning PCR primers  
Short hairpin NRF2 Forward:GATCCCCCCAAAGCTAGTATAGCAAT
AATTCAAGAGATTATTGCTATACTAGCTTTGG
TTTTTA 
Reverse:AGCTTAAAAACCAAAGCTAGTATAGC
AATAATCTCTTGAATTATTGCTATACTAGCTTT
GGGGG 
Short hairpin p21 Forward:GATCCCCGACCAGCCTGACAGATTT
CTATTCAAGAGATAGAAATCTGTCAGGCTGG
TCTTTTTA 
Reverse:AGCTTAAAAAGACCAGCCTGACAGA
TTTCTATCTCTTGAATAGAAATCTGTCAGGCT
GGTCGGG 
Real-Time PCR primers  
Mouse actin Taqman primer from Applied Biosystems 
Cat. Mm02619580_g1 
Mouse HO-1 Taqman primer from Applied Biosystems 
Cat. Mm00516005_m1  
Mouse NQO1 Taqman primer from Applied Biosystems 
Cat. Mm01253561_m1  
Mouse p21 Taqman primer from Applied Biosystems 
Cat. Mm04205640_g1 
ChIP p21 Forward: AGGTCAGCTAAATCCGAGGAGGAA 
Reverse: TCCTGCTTTGGAGAAGCTGTGAGT‟ 
ChIP Mdm2 Forward: TCGGAGGAGCTAAGTCCTGA 
Reverse: CGGCAATAGCTCTCAAATGC 
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3.1.9 Cells 
Name Description Source 
B-Lymphoma cells Primary murine myc-driven 
B-cell lymphoma cells 
Lab made 
MEF murine embryonic fibroblast Lab made 
NIH 3T3 mouse embryonic fibroblast ATCC 
Pheonix human embryonic kidney line Clontech/Takara 
 
3.1.10 Solutions and buffers: 
Transfection solutions  
2 M CaCl2  2.99 g in 10 mL dH2O,  
filter (0.2 μm) 
store at -20°C 
2x HBS (Hepes buffered saline) 280 mM NaCl 
10 mM KCl 
1.5 mM Na2HPO4 x 2H2O 
12 mM Dextrose 
50 mM HEPES 
100 mL dH2O, pH 7.05 
filter (0.2 μm) 
store at -20°C 
100 mM Chloroquine  
 
0.516 g Chloroquine diphosphate 
10 mL dH2O 
filter (0.2 μm) 
store at -20°C 
Western blotting solutions  
Protein lysis buffer (RIPA) 0.5% NP-40 
0.5% TritonX-100 
50 mM Tris-HCl pH 7.4 
150 mM NaCl 
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0.1% SDS 
0.5% sodium deoxycholate 
store at -20°C 
Protein lysis buffer (for IP) 0.5% NP-40 
0.5% TritonX-100 
50 mM Tris-HCl pH 7.4 
150 mM NaCl 
10% glycerol 
1 mM DTT 
1 x protease inhibitor cocktail 
(Roche) 
store at -20°C 
SDS sample buffer 1 ml 0.5 M Tris-HCl (pH 6.8) 
0.8 ml Glycerol 
1.6 ml 10% SDS 
0.4 ml 14.3 M β-mercaptoethanol 
0.4 ml of 1% Bromephenol blue 
store at -20°C 
1 M Tris-HCl pH 6.8 12.11 g Tris base, pH 6.8,  
100 ml dH2O 
1.5 M Tris-HCl, pH 8.8 18.16 g Tris base, pH 8.8,  
100 ml dH2O  
10% APS 1 g Ammonium peroxysulfate in  
10 ml dH2O 
10 x Running buffer (pH 8.3) 30 g Tris base 
144 g Glycine 
10 g SDS 
1 L dH2O pH 6.8 
Transfer Buffer 2.9 g Tris base 
14.5 g glycine 
200 ml methanol 
1 L dH2O, store at 4°C  
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25 x TBS 
 
60 g Tris base 
200 g NaCl 
9.5 ml 10 N HCl 
1 L dH2O  
1 x TBS-Tween (TBS-T)  0.2 % Tween 20 in TBS 
Blocking solution 5 % dry milk in 1 x TBST 
prepare freshly 
Crystal violet staining solution  
(0.5% m/V) 
 
 
0.5 g crystal violet powder  
80 mL dH2O 
20 mL methanol 
 
3.1.11 Media 
Medium Component 
DMEM medium 
 
DMEM 
+ 10% FCS 
+ Penicillin-streptomycin (100 U/ml) 
store at 4°C 
B cell medium DMEM + IMDM (1:1) 
+ 10% FCS 
+ Penicillin-streptomycin (100 U/ml) 
+ 4 mM L-Glutamine 
+ 25 μM β-mercaptoethanol 
store at 4°C 
Freezing medium FCS + 10 % DMSO 
store at 4°C 
LB-Medium 10 g Trypton 
5 g Yeast Extract 
10 g NaCl 
adjust to 1 L with dH2O (pH 7.2-7.5) 
store at 4°C 
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LB-bacteria plates 10 g Trypton 
5 g Yeast Extract 
10 g NaCl 
15 g Agar Agar 
adjust to 1 L with dH2O (pH 7.2-7.5) 
store at 4°C 
 
3.2 Methods 
3.2.1 Molecular Cloning of DNA constructs (shRNA constructs) 
3.2.1.1 Annealing oligos 
PCR primers were designed and used for respective DNA targets. Annealing 
reactions were performed in a total volume of 50 μl. 
Components: 
Forward primer (10 μM) 1 μl 
Reverse primer (10 μM) 1 μl 
Annealing buffer 48 μl 
Conditions: Incubated the mixture at 95°C for 5min, and then slowly cooled the 
annealed oligos to room temperature. The annealed oligo inserts can be used 
immediatedly in a ligation reaction. 
 
3.2.1.2 Ligation into psuper vector 
Assemble the cloning reaction as follows: 
Purified linearized psuper vector 1 μl 
The annealed oligos 3 μl 
T4 DNA ligase buffer 1 μl 
dH2O Add H2O to 10 μl 
Incubated overnight at 16°C. 
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3.2.1.3 Bacteria transformation 
Ligation product (10 μl) was mixed with 50 μl competent DH5α E.coli in 1.5 ml 
eppendorf tube and incubated on ice for 20 minutes. Then the cells were heat 
shocked at 42°C for exactly 90s and quickly put back on ice for 2 minutes. 
After adding 1 ml LB medium, the tube was incubated in a 37°C shaker for 45 
minutes. Bacteria was pelleted and plated on LB-agar plates with 100 μg/ml 
ampicillin, and incubated at 37°C overnight. 
 
3.2.1.4 Plasmid mini-preparation and maxi-preparation 
Individual colony was picked and incubated in 3 ml LB medium (100 μg/ml 
ampicillin) at 37°C overnight. Bacteria was centrifuged at 3000 rpm (5 minutes, 
4°C) and pellet was resuspended, lysed, precipitated by sequentially adding 
100 μl ice-cold Solution I, 200 μl freshly prepared Solution, 150 μl of ice-cold 
Solution III. After centrifugation (14000 rpm, 10 minutes, 4°C), supernatant 
was transferred to a new Eppendorf cup and 1 ml of ethanol was added to 
precipitate DNA. After vortexing and centrifugation (14000 rpm, 10 minutes, 
4°C) the pellet was washed with 1 ml of 70% ethanol. DNA was air-dried and 
dissolved in 30 μl dH2O.  
Maxi-preparation of plasmid, which can be used for mammalian cell 
transformation, was made with Invitrogen maxi-prep kit.  
 
3.2.1.5 Sequencing of DNA 
The DNA sequencing was performed by Source BioScience LifeSciences 
(MDC, Berlin). 
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3.2.2 Cell culture  
3.2.2.1 Primary MEF isolation  
Primary p53-/- MEFs were isolated from E13.5 mouse embryos. The mice were 
sacrificed at gestational day E13.5 by CO2 euthanasia. Opened the abdominal 
cavity and resected the uterus (resembling a „perl chain‟ with each „pearl‟ 
reflecting an embryo). Two sets of 10 cm plates and two sets of eppendorf 
tubes were labeled for each embryo. Dissected one of the 'pearls‟, opened the 
maternal part of the placenta (cut it off), and released the embryo into PBS. 
Dissected the thin surrounding membrane, the yolk sac, and saved it in an 
eppendorf tube (for PCR-genotype). Resected all the internal organs and 
vessels and save the head in another eppendorf tube (for PCR-genotype). 
Transferred the embryo in a plate with 1 ml of trypsin and disrupted it with a 
scalpel and a syringe with a 18G needle. The plate was incubated for about 20 
min at 37°C. The trypsin-cell suspension was resuspend by pipetting up and 
down and transferred into a 75 cm2 flask. Medium was changed after the first 
day and every other day thereafter. 
 
3.2.2.2 Primary lymphoma isolation  
C57BL/6 background Eμ-myc transgenic mice with p53+/- phenotype were 
monitored for lymphoma onset. The mice were sacrificed when the lymphomas 
became greater than 5mm in diameter. The enlarged lymph nodes were 
excised after CO2 euthanasia of the mice. Single cell suspensions were 
produced using the gentleMACSTM, Miltenyi instrument. For histopathological 
analysis, the lymph nodes were snap-frozen or formalin-fixed as described 
previously (Schmitt et al., 2002a). 
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3.2.2.3 Adherent cell culture 
NIH 3T3 and Phoenix cells were cultivated at 37°C in an incubator with 5% 
CO2, 20% O2, and 95% humidity atmosphere. Murine embryonic fibroblasts 
(MEFs) were cultivated at 37°C in an incubator with 5% CO2, 3% O2, and 95% 
humidity atmosphere. Cells were grown in tissue culture treated petri-dishes. 
Cell culture media were renewed every 2 – 3 days. Almost confluent (80-90%) 
grown cells were split onto new dishes. When splitting, medium was removed 
and cells were washed twice with PBS. Trypsin/EDTA solution was added and 
the plate was incubated at 37°C for several minutes to detach the cells. 
Trypsinization was inhibited by adding fresh medium. Cells were mixed well 
and seeded on new dishes. 
 
3.2.2.4 Suspension cell culture 
Preparation of feeder cells: When NIH 3T3 cells reached 70-80% confluency, 
cells were irradiated with 20 Gy (3000rad) and incubated under standard 
conditions for another 12 hours. Afterwards, cells were split according to 
standard procedures and resuspended in fresh B cell medium. Cells were 
counted by trypan blue exclusion and re-seeded into 6-well plates at a density 
of 1 x 105 cells /well. These feeder cells could be used for lymphoma cell 
culture 12 hours later. Medium was changed every 2 – 3 days until feeder 
plates were not used when they got flattened or vacuole rich. Medium enriched 
with growth promoting factors of irradiated 3T3 cells (12 to 24 hours after 
plating feeder cells) was used as “conditioned medium” for cytotoxic treatment 
of lymphoma cells. 
Culture of mouse B lymphoma cells: Lymphoma cells were plated at a 
subconfluent density (ca. 70%) on conditioned 3T3 feeder layer and cultivated 
under standard conditions (37°C, 5% CO2, 3% O2, 95% humidity). Cells were 
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grown until they grew too dense or medium turned too acidic. For splitting, 
about 1/3 of the cell suspension was removed (cultivated on new feeder plates 
with fresh medium, frozen or discarded). Feeder cell plates were changed after 
5 – 7 days of culture or when feeder turned too old. For this, the plate was 
gently rinsed to remove lymphoma cells sticking on the feeders and 
suspension was centrifuged at 1,200 rpm for 5 min (4°C). A few ml of the 
supernatant were retained to resuspend the cell pellet and cell suspension was 
subsequently transferred to a new feeder plate. Splitting was considered as 
one passage. Lymphomas cells were only used at a viability of more than 50% 
and at low passages (to prevent selection for clones that have gained 
mutations by long-term culture). 
 
3.2.2.5 Thawing and freezing cells 
Thawing: Cryovials containing the frozen cells were removed from liquid 
nitrogen and placed into a 37°C water bath immediately. In order to minimize 
the toxic effect of the DMSO, 5 ml fresh growth medium was added and cells 
were pelleted by centrifugation at 1,200 rpm for 5 min (4°C). The cell pellet 
was resuspended, seeded on tissue culture dishes (or feeder plates) and 
cultivated in the incubator.  
Freezing: Cells were trypsinized out (adherent cells) or rinsed out (suspension 
cells) from culture dish, pelleted down and resuspended in ice-cold freezing 
medium and transferred into sterile 1.5 or 2 ml cryovials. Then cells were put 
into “Mr. Frosty” box and immediately transferred to -80°C freezer .For long 
term storage, cells were stored in liquid nitrogen. 
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3.2.3 Cell transfection and infection 
Low passage Phoenix cells were grown in a 10 cm petri-dish to a maximal 
density of 70%. Twenty micrograms retroviral plasmid, 15 μg helper plasmid 
and 62.5 μl CaCl2 were mixed in a FACS tube and adjusted with sterile water 
to 500 μl. After adding 500 μl 2 x HBS dropwise under constant agitation (air 
bubbles), DNA precipitation occurred within 5 minutes at RT. Meanwhile, old 
medium of Phoenix cells was exchanged with 10ml new DMEM. Subsequently, 
25 µΜ chloroquine and the precipitate (1 ml) were added into DMEM. After 12 
hours incubation, medium including the precipitate was replaced by 4 – 5 ml of 
new medium for collecting virus supernatant. 
Cells about to be infected were seeded at subconfluent density 12 hours after 
Phoenix cell transfection. The first virus supernatant was harvested within 24 
hours after transfection by aspiration and filtered through a 0.45 μm filter. 
Medium was removed from the cells and virus supernatant containing 4 μg/ml 
polybrene was added. New medium (4 – 5 ml) was added to the Phoenix cells 
for the next round of infection. Afterwards, cells were incubated and grown 
under standard conditions. 
After 12 hours of incubation, the second virus supernatant was harvested 
according to the procedure above, supplemented with 4 μg/ml polybrene and 
added to cells. After spinoculation of the plates (1,500 rpm, 10 minutes, 32°C), 
cells were incubated and grown until the next round of transduction. In addition, 
new medium was added to the Phoenix cells for the next round of transduction. 
The third and fourth virus supernatants were collected 12 hours and 24 hours 
later according to the procedure above. 
Twelve hours after the last transduction, medium was removed from the cells 
and fresh DMEM medium was added. Cells were grown for approximately 24 
hours to allow cells to express the gene of interest. Cell population was 
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selected with puromycin (~2 days) or hygromycin (~5 days) until 
non-transduced cells were completely dead.  
 
3.2.4 Cell Viability, Apoptosis 
3.2.4.1 Assessment of cell viability 
The Guava ViaCount assay was performed using a Guava easyCyte flow 
cytometer and the Guava CytoSoft software package. Cells were harvested 
and resuspended in a small volume of 1 x PBS (e.g. 500 μl). One hundred 
microliters of resuspention was transferred into 96-well plate and the Guava 
ViaCount reagent was added as 1:1, viable and dead cells were separated 
using the viability (PM1) vs nucleated cells (PM2) plot. For viability assessment 
and cytotoxicity assays, 1,000 cells were counted in total (dead and alive). 
Percentage of viability was indicated as the ratio of living cells to the whole cell 
number.  
 
3.2.4.2 Assessment of apoptosis 
Cells were treated with H2O2 for 24 hours and co-stained with Annexin V and 
propidium iodide (PI) according to the manufacturer‟s instructions. Apoptotic 
cells were separated and quantified by FACS. 
 
3.2.5 Intracellular ROS detection 
MEFs were treated with piperlongumine for 1 hour or 2 hours alone or together 
with antioxidant (or inhibitors), washed with 1 x PBS, and incubated with 
H2DCFDA (10 μM) for 30 minutes. Cells were then washed 2 times with 
ice-cold 1 x PBS and harvested for FACS analysis. 
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Lymphomas were treated with piperlongumine for 2 hours alone or together 
with inhibitors, and incubated with CellROX green reagent (5 μM) for 30min. 
Cells were then harvested, washed 2 times with ice-cold 1 x PBS and analyzed 
by FACS. 
 
3.2.6 Immunoassays 
3.2.6.1 Immunoblotting (western blot) 
Thirty to sixty micrograms of protein samples were loaded in polyacrylamide 
gel and gel was run at 80 volts (120 volts after proteins ran through stacking 
gel) in 1x running buffer. After electrophoresis, proteins were transferred to 
PVDF membrane using semi-dry transfer chamber (BioRad). Afterwards, 
membrane was blocked with 5% milk in PBST for 1 hour and then incubated 
with appropriately diluted primary antibody solution (5% BSA in PBST) at 4°C 
overnight. The blot was washed 3 times for 10 minutes with PBST and later 
incubated with appropriate secondary antibody for 1 hour at room temperature. 
The blot was again washed 3 times for 10 minutes with PBST and 
chemiluminescent peroxidase substrate was applied on the membrane. 
Images were visualized and taken by Intas Chemocam Imager (or ChemiDoc 
MP Imaging System). 
 
3.2.6.2 Immnunoprecipitation (IP) 
Cells were lysed in protein lysis buffer (IP) and the lysates were then 
immunoprecipitated with p53 antibody (Ab-1) or isotype-matched control 
antibody (mouse IgG) plus magnetic Dynabeeds (Thermo Fisher Scientific) for 
overnight. Beads were washed 3 times with lysis buffer (IP) plus 1 time with 
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ice-cold 1 x PBS and boiled in SDS loading buffer. Protein samples were 
analyzed by immunoblotting. 
 
3.2.6.3 Chromatin Immunoprecipitation (ChIP) 
ChIP assays were performed using the iDeal ChIP-seq kit for transcription 
factors with antibody specific to p53 (both wild-type and mutant) according to 
the manufacturer‟s instruction. Immunoprecipitated DNA samples and 10% of 
inputs were PCR-amplified with primer pairs specific for the promoters of p21 
and Mdm2 genes.  
 
3.2.7 Quantitative real-time PCR 
Total RNA was prepared using the TRIzol reagent (Invitrogen). Oligo 
(dT)-primed complementary DNA was synthesized with the SuperScript III 
reverse transcriptase (Invitrogen). Real time quantitative PCR (RQ-PCR) 
analysis was performed using the TaqMan Gene Expression assay (Applied 
Biosystems) with the housekeeping gene actin as an internal control. All 
reactions were performed in triplicates. Relative transcripts levels were 
calculated based on the comparative △△ cycle threshold method.  
 
3.2.8 Metabolic measurement 
Oxidative phosphorylation and glycolysis flux analysis was measured by 
Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience), in accord 
with the manufacturer's recommendations. For these assays, about 2 x 104 
cells were seeded on XF24 cell culture plates (Seahorse Biosciences) and 
grown to 80% confluency prior to analysis. On the day of assay, culture media 
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were changed to XF Assay medium (Seahorse Biosciences), supplemented 
with 10 mM glucose, 1 mM sodium pyruvate, and 2 mM glutamine for oxidative 
phosphorylation assay and supplemented with only 2 mM pyruvate for assay 
of glycolysis rates. Prior to assay, plates were transferred into a non-CO2 
incubator at 37 °C and kept for 1 hour. To quantify oxidative phosphorylation 
rates, I first measured initial (basal) oxygen consumption rates (OCR), 
followed by a series of changes in oxygen consumption when cells were 
sequentially treated with 1 μM oligomycin, 2 μM carbonyl cyanide 
3-chlorophenylhydrazone (CCCP), and finally 1 mM antimycin A. Following 
each addition, oxygen levels in the culture medium were monitored at 10 
minutes intervals and the overall OCR was calculated. For the glycolysis stress 
test, after collecting baseline extracellular acidification rate (ECAR) data, cells 
were sequentially treated with 10 mM glucose and 1 mM oligomycin and 
evoked changes in ECAR were quantified after each addition. For this purpose, 
changes in culture medium pH was monitored every 10 minutes and used to 
calculate the overall ECAR. 
Once the OCR or ECAR measurement was finished, the cell culture plate was 
ejected from the XF24 analyzer. To measure the protein concentration in cell 
culture plate, the medium was sucked out and 100 μl M-PER™ mammalian 
protein extraction reagent (Pierce) was added for 5 min, and BCA protein 
assay kit (Pierce) was used for measuring the protein concentration. These 
protein amounts were used to normalize either OCR or ECAR. 
 
3.2.9 Statistical analyses 
Statistical differences between two experimental groups were calculated using 
unpaired two-tailed Student's t-test. Statistical differences of cells were 
calculated using two-way ANOVA test. Significance level: ***, p < 0.005; **, p < 
0.01; *, p < 0.05. 
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4 RESULTS 
4.1 Generation of in vitro cell model system 
To set up the in vitro model system, lab made primary Eμ-myc lymphoma cells 
and mouse embryonic fibroblasts (MEFs) were chosen for the subsequent 
experiments. Primary lymphoma cell populations were isolated from Eμ-myc 
transgenic mice harboring enlarged peripheral lymph nodes, and cultured 
single-cell suspensions on feeder layers. Eμ-myc transgenic mouse, a 
well-established model for human non-Hodgkin‟s lymphomas, develops pre-B 
or B cell lymphoma by several months of age (Schmitt et al., 2002a; Schmitt et 
al., 2002b), and can be used to study p53 function during tumor development 
and treatment sensitivity in spontaneous B-cell malignancies. C-myc 
oncogene is constitutively expressed in Eμ-myc transgenic mouse under the 
control of the Ig heavy-chain enhancer (Eμ) in the B-cell lineage (Adams et al., 
1985). Moreover, the development of lymphomas in the Eμ-myc mouse 
frequently involves the acquisition of additional mutations, giving rise to 
heterogeneity of the resulting tumors that can serve as a model for the 
heterogeneity of human cancer. In addition to Eμ-myc lymphoma cells, I also 
included MEFs, which were stably introduced with the same oncogene myc in 
the first place to generate comparable system. MEF was chosen as a different 
cell type other than Eμ-myc lymphoma cell not only because it is a primary cell 
with less spontaneous variability but also simple and easy to handle. 
Most often experiments were done in both p53+/- lymphoma cells and myc; 
p53-/- MEFs (referred to as p53-/- MEFs in the following). Of note, p53+/- 
lymphoma cells arising in p53+/- mice invariably lose the wild-type p53 allele 
because of loss of heterozygosity of p53 gene and become p53 null (referred 
to as p53 null lymphoma cells in the following). To generate „matched sets‟ of 
cells differing only in p53 mutant status, I separated each p53 null lymphoma 
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populations or p53-/- MEFs into seven parallel cultures and infected either with 
an empty vector (MSCV-control) or six hotspot mutants, p53R172H, p53G242S, 
p53R245Q, p53R246S, p53R270H and p53R279Q.  
To characterize each sets of cells, I compared the proliferation rate of p53-/- 
MEFs harboring these p53 mutants for 72 hours. Cell proliferation was 
monitored by growth curve analysis: all six p53 mutants proliferated faster than 
the empty control MEFs (Figure 7).  
 
Figure 7: Proliferation rates of p53-/- MEFs harboring p53 mutants. Proliferation 
assays of p53 mutants and empty control in p53-/- MEFs. Data are representative of 
three independent experiments. 
 
To get an overview of metabolic feature in p53-/- MEFs with p53 mutants, both 
mitochondrial respiration and glycolytic function were measured using a 
Seahorse XF24 Extracellular Flux Analyzer. Figure 8A showed the profile of 
the key parameters of mitochondrial respiration, including basal respiration 
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(shows energetic demand of the cell under baseline conditions), ATP 
production (shows ATP produced by the mitochondria that contributes to 
meeting the energetic needs of the cell), maximal respiration (shows the 
maximum rate of respiration that the cell can achieve), and spare respiratory 
capacity (indicates the extra capacity available in cells to produce energy in 
response to increased stress). The profile of the key parameters of glycolytic 
function (Figure 8B), including glycolysis (the process of converting glucose to 
pyruvate), glycolytic capacity (the maximum ECAR rate reached by a cell 
following the addition of oligomycin, which could effectively shut down 
OXPHOS and drive the cell to use glycolysis to its maximum capacity), and 
glycolytic reserve (indicates the capability of a cell to respond to an energetic 
demand as well as how close the glycolytic function is to the cell‟s theoretical 
maximum). Results showed that the oxygen consumption rate (OCR), an 
indicator of OXPHOS, was slightly higher in cells harboring p53G242S, p53R245Q, 
p53R246S and p53R270H-mutant in the basal state when compared to the empty 
control and p53R172H and p53R279Q-mutant (Figure 8C, E), whereas the basal 
extracellular acidification rate (ECAR), a consequence of lactic acid production 
(which is indicative of glycolysis), was lowest in cells harboring 
p53G242S-mutant but had no obvious difference in the empty control and the 
other p53 mutant cells (Figure 8D, E). Strikingly, treatment of cells harboring 
the empty control and p53 mutants with CCCP elicited a very modest or no 
increase in oxygen consumption (Figure 8C), indicative of a minimal 
mitochondrial respiratory capacity. Together, above results suggested that 
these p53 mutants caused a minor alteration in metabolic features in overall. 
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Figure 8: Metabolic feature of p53-/- MEFs with p53 mutant. (A) Using the XF-24 
Extracellular Flux Analyzer, OCR was measured prior to the addition of drugs (basal 
OCR) and then following the addition of the indicated drugs. Reduction in OCR after 
oligomycin indicates the amount of oxygen consumed for mitochondrial ATP 
generation. After CCCP (an uncoupling agent) the maximum capacity of the 
mitochondria to use OXPHOS is revealed. Spare capacity is the difference between 
maximal respiration and basal respiration. Antimycin A, a complex III inhibitor, renders 
a complete shutdown of the ETC. Adapted from Seahorse Bioscience website. (B) 
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ECAR was measured prior to the addition of glucose and then following the addition of 
the indicated materials. Glucose fuels glycolysis. Oligomycin inhibits ATP synthase in 
the mitochondria resulting in an increased dependence on glycolysis. Glycolytic 
reserve is the difference between glycolytic capacity and glycolysis. 2-DG is a 
competitive inhibitor of glucose, and functions to shut down glycolysis. Adapted from 
Seahorse Bioscience website. (C) and (D) OCRs and ECARs in p53-/- MEFs were 
detected as described in (A) and (B). (E) Basal glycolytic and respiration rates are 
summarized. Data are representative of three independent experiments.  
 
4.2 Cytotoxic effects by metabolic inhibitors 
To identify the metabolic vulnerabilities of these p53 mutants, I performed a 
cytotoxic screening using specific inhibitors, which can trigger metabolic stress 
in cells. 2-Deoxy-D-glucose (2-DG), Etomoxir and bis-2-(5-phenylacetamido-1, 
2, 4-thiadiazol-2-yl) ethyl sulfide (BPTES) are specific inhibitors of the 
energy-generating catabolic pathways. 2-DG is a glucose analog that inhibits 
hexokinase, the first enzyme required for glycolysis. It has been shown that 
2-DG exhibits cytotoxic effect in many cancer cells, especially those with 
defects in mitochondrial respiration or cells in hypoxic environment (Liu et al., 
2001; Liu et al., 2002; Maher et al., 2004). Etomoxir is an irreversible inhibitor 
of the carnitine palmitoyltransferase (CPT1) enzyme that decreases 
β-oxidation in the mitochondria, and described to have effects on tumor 
survival (Hernlund et al., 2008; Samudio et al., 2010). BPTES is a selective 
inhibitor of glutaminase 1 (GLS1), which leads to inhibition of glutaminolysis, 
and can effectively inhibit tumor growth (Elgogary et al., 2016; Lee et al., 2016; 
Seltzer et al., 2010). However, as shown in figure 9, none of these inhibitors 
exhibited effective cytotoxic activities in p53-/- MEFs harboring p53 mutants 
compared with the empty control cells, suggesting these mutants may not 
have any impact on glycolysis, FAO and TCA cycle pathways. 
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Figure 9: Cytotoxic effects by specific metabolic inhibitors in p53-/- MEFs. 
Relative cell viability analyses of p53-/- MEFs treated with 5 mM 2-DG for 24 h or 48 h 
(A); 200 μM Etomoxir for 24 h (B); 50 μM BPTES for 24 h (C), normalized to the native 
control of same group. Experiments were done in two independent p53-/- MEFs. Data 
are presented as mean ± SD. 
 
4.3 p53-/- MEFs harboring p53R245Q, p53R246S and p53R270H-mutant are 
more sensitive to oxidative stress 
ROS have been considered as by-products of aerobic metabolism and have 
important roles in cell signalling and homeostasis (Giorgio et al., 2007). The 
increase of ROS in tumor cells may play an important role in the initiation and 
progression of tumor (Engel and Evens, 2006; Trachootham et al., 2009). 
However, as excessive levels of ROS can also be toxic to the cells, tumor cells 
with increased oxidative stress are likely to be more vulnerable to damage by 
further ROS insults induced by exogenous agents, which may provide a 
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selective mechanism to induce tumor cell death (Pelicano et al., 2004; 
Trachootham et al., 2009).  
To examine the effect of exogenous oxidative stress on p53-/- MEFs, H2O2, the 
simplest peroxide, was used as an inducer. H2O2 induced cell death in MEFs 
regardless of its p53 mutant status. Interestingly, MEFs containing p53R245Q, 
p53R246S and p53R270H-mutant underwent massive cell death compared with 
the empty control and other three p53 mutants (Figure 10A). Apoptosis were 
further verified by Annexin V and propidium iodide (PI) double staining in cells 
with those three mutants (Figure 10B). Consistently, there were less viable 
cells left in the wells seeded with p53R245Q, p53R246S and p53R270H-mutant 
MEFs than that with the empty control and other three p53 mutant MEFs in 
response to 24 h treatment of 1 mM H2O2 showed by crystal violet analyses 
(Figure 10C). 
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Figure 10: p53-/- MEFs harboring p53R245Q, p53R246S and p53R270H-mutant are more 
sensitive to H2O2 treatment. (A) Relative cell viability of p53
-/- MEFs after exposure 
to H2O2 at the indicated concentrations for 24h, normalized to the native control of 
same group. Experiments were done in three independent p53-/- MEFs. Data are 
presented as mean ± SD. (B) Annexin V and PI double staining analyses of p53-/- 
MEFs after treated with 1 mM H2O2 for 24h by FACS. The cells in Q2 plus Q3 
represent apoptotic cells. (C) The statistical analysis of the results from (B) (n=3). 
Data are presented as mean ± SD. ***, p < 0.005, p53R245Q, p53R246S and 
p53R270H-mutant vs the empty control. (D) Crystal violet analyses of p53-/- MEFs as in 
(B). 
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Furthermore, tert-Butyl hydroperoxide (tBHP), another oxidative stress inducer, 
could also cause significant cell death both in p53-/- MEFs and p53 null 
lymphomas harboring p53R245Q, p53R246S and p53R270H-mutant compared with 
the empty control and other three p53 mutants (Figure 11). 
 
Figure 11: p53-/- MEFs and Eµ-myc p53 null lymphoma cells harboring p53R245Q, 
p53R246S and p53R270H-mutant are more sensitive to tBHP treatment. Relative cell 
viability analyses of p53-/- MEFs (A) or Eµ-myc p53 null lymphoma cells (B) treated 
with 30 μM tBHP for 6h relative to native cells of same group. Experiments were done 
in three independent p53-/- MEFs or Eµ-myc p53 null lymphoma cells. Data are 
presented as mean ± SD; ***, p < 0.005, p53R245Q, p53R246S and p53R270H-mutant vs 
the empty control. 
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Taken together, the above results obtained by H2O2 or tBHP treatment 
suggested that cells harboring p53R245Q, p53R246S and p53R270H-mutant are 
more sensitive to exogenous oxidative stress than the empty control and other 
three p53 mutants. This also indicated that p53R245Q, p53R246S and 
p53R270H-mutant possess oncogenic gain-of-function and affect cellular 
response to oxidative stress. 
 
4.4 Piperlongumine induces significant cell death in cells harboring 
p53R245Q, p53R246S and p53R270H-mutant 
Piperlongumine, a natural product isolated from long pepper, is a well-known 
oxidative stress inducer. In a cell-based small-molecule screening study, 
piperlongumine was identified to be the most reliable and potent compound 
that can selectively kill many types of solid tumor cells and 
oncogene-transformed cells but not normal cells by inducing the accumulation 
of ROS (Raj et al., 2011). Recently, piperlongumine was also found to induce 
effective killing in primary myeloid leukemia cells from patients (Xiong et al., 
2015). Thus, I decided to take advantage of piperlongmine to induce oxidative 
stress. 
To confirm that piperlongumine has similar cytotoxic effect as H2O2 and tBHP, I 
tested the effect of piperlongumine on the viability of p53-/- MEFs and p53 null 
lymphoma cells. As expected, piperlongumine resulted in massive cell death 
both in MEFs (Figure 12A, B) and lymphoma cells (Figure 12C) harboring 
p53R245Q, p53R246S and p53R270H-mutant (referred to as 
piperlongumine-sensitive mutants in the following) compared with the empty 
control at the dose when the empty control and other p53 mutant cells showing 
moderate response.  
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Figure 12: Piperlongumine induces significant cell death in MEFs and 
lymphoma cells harboring p53R245Q, p53R246S and p53R270H-mutant. (A) Relative cell 
viability analyses of p53-/- MEFs treated with 10 μM or 15 μM piperlongumine for 6 h, 
normalized to the native control of same group. (B) Relative cell viability analyses of 
MEFs treated with 10 μM piperlongumine for 4 h or 8 h, normalized to the native 
control of same group. (C) Relative cell viability analyses of Eµ-myc p53 null 
lymphoma cells treated with 25 μM piperlongumine for 6h, normalized to the native 
control of same group. Experiments were done in three independent p53-/- MEFs or 
Eµ-myc p53 null lymphoma cells. Data are presented as mean ± SD; ***, p < 0.005, 
p53R245Q, p53R246S and p53R270H-mutant vs the empty control. 
 
Since wild-type p53 could induce a variety of antioxidant genes to exert its 
antioxidant function, it is probable that cells harboring wild-type p53 would 
possess intact redox regulatory mechanisms, which ensure them less 
vulnerable to oxidative stress imposed by piperlongumine. p53-/- MEFs were 
introduced with the empty control or wild-type p53 to generate comparable 
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system. However it was very difficlut to introduce wild-type p53 in p53 deficient 
cells because high expression of wild-type p53 would induce cell apoptosis. To 
this end, I performed piperlongumine treatment in these comparable MEFs 
without puromycin selection. As expected, piperlongumine caused a stronger 
cytotoxic effect in the empty control MEFs compared to MEFs with wild-type 
p53 in a dose-dependent manner (Figure 13). 
 
Figure 13: p53-/- MEFs with wild-type p53 are less vulnerable to piperlongumine 
treatment. Relative cell viability analyses of p53-/- MEFs treated with piperlongumine 
at the indicated concentrations for 6 h. Experiments were done in two independent 
p53-/- MEFs. 
 
Piperlongumine is considered as a cancer cell-specific ROS inducer (Raj et al., 
2011), and previous studies have demonstrated that piperlongumine induces 
accumulation of ROS in various cancer cell lines (Golovine et al., 2013; Halasi 
et al., 2013; Liu et al., 2014c). To validate piperlongumine-induced cell death is 
due to the accumulation of intracellular ROS caused by piperlongumine, I 
measured ROS levels after piperlongumine treatment using the fluorescent 
ROS indicator H2DCFDA (in MEFs) or CellROX Green Reagent (in lymphoma 
cells), both common ROS detection reagents which generate green 
fluorescence in the presence of ROS. The fluorescent intensities 
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demonstrated the relative cellular ROS levels were increased at 2 h after 10 
μM (Figure 14A) and 25 μM (Figure 14B) piperlongumine treatment in MEFs 
and lymphoma cells. Those harboring piperlongumine-sensitive mutants 
showed higher ROS level than the empty control and other three p53 mutants 
although initial (no piperlongumine treatment) ROS level was comparable to 
each other. Piperlongumine induced ROS accumulation was abolished when 
co-treated with the antioxidant agent N-acetyl-L-cysteine (NAC, 3 mM) 
bringing all cells back to similar level (Figure 14A). In addition, piperlongumine 
induced cell death could also be blocked when co-treated with NAC (Figure 
15). Taken together, these data demonstrated that piperlongumine induced 
cell death via ROS-dependent mechanism. 
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Figure 14: Piperlongumine induces ROS accumulation. (A) ROS level in p53-/- 
MEFs 2 h after piperlongumine treatment. MEFs were treated with 10 μM 
piperlongumine alone or co-treated with 3 mM NAC for 2 h and stained with 
H2DCFDA. The mean H2DAFDA fluorescent intensity (representing cellular ROS 
level) was measured by FACS. (B) ROS elevation in Eµ-myc p53 null lymphoma cells 
2 h after piperlongumine treatment. Lymphoma cells were treated with 25 μM 
piperlongumine for 2 h and stained with CellROX Green Reagent. The mean CellROX 
fluorescent intensity (representing cellular ROS level) was measured by FACS. 
Experiments were done in three independent p53-/- MEFs or Eµ-myc p53 null 
lymphoma cells. Data are presented as mean ± SD; *, p < 0.05, p53R245Q, p53R246S and 
p53R270H-mutant VS p53R172H, p53G242S and p53R279Q-mutant. ***, p < 0.005, p53R245Q, 
p53R246S and p53R270H-mutant vs the empty control. 
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Figure 15: Piperlongumine-induced cell death can be rescued by NAC 
co-treatment. Relative cell viability analyses by Guava ViaCount assay. (A) p53-/- 
MEFs treated with 10 μM piperlongumine alone or co-treated with 3 mM NAC for 6 h, 
normalized to the native control of same group. (B) Eµ-myc p53 null lymphoma cells 
treated with 25 μM piperlongumine alone or co-treated with 3 mM NAC for 6 h, 
normalized to the native control of same group. Experiments were done in three 
independent p53-/- MEFs or Eµ-myc p53 null lymphoma cells. Data are presented as 
mean ± SD; ***, p < 0.005, p53R245Q, p53R246S and p53R270H-mutant vs the empty 
control. 
 
4.5 Piperlongumine induces apoptosis via ROS-dependent p38 and 
JNK activation 
Previous studies have shown that p38 and c-Jun N-terminal kinases (JNK), 
mitogen-activated protein kinase (MAPK) family members, are two canonical 
ROS-activated signaling proteins that control cell death under oxidative stress 
(Gomez-Lazaro et al., 2007; Xiao et al., 2011). To examine the effects of 
piperlongumine on p38 and JNK activation, immunoblotting analyses of 
phospho-p38 (p-p38) and phospho-JNK (p-JNK) were performed. As shown in 
Figure 16, the phosphorylation of both increased after piperlongumine 
treatment, more prominently in cells harboring piperlongumine-sensitive 
mutants than the empty control and other three mutants. Interestingly, 
although piperlongumine enhanced the phosphorylation of extracellular 
signal-regulated kinases (Erk), a MAPK family member reported to be involved 
in piperlongumine‟s biological activities (Bezerra et al., 2013), there was no 
significant difference in levels of phospho-Erk (p-Erk1/2) between p53 mutants 
and the empty control upon piperlongumine treatment (Figure 16B and Figure 
17). In addition, a significant increase in the levels of cleaved caspase 3, an 
apoptotic marker, was also observed upon piperlongumine treatment reflecting 
apoptosis result (Figure 17). By abolishing Piperlongumine-induced ROS 
(Figure 14), NAC co-incubation with piperlongumine almost completely 
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abolished piperlongumine-induced activation of p38, JNK and cleaved 
caspase 3 (Figure 17). 
 
Figure 16: Piperlongumine activates p38 and JNK. Immunoblotting analyses of 
p-p38, p38, p-JNK, JNK, p-Erk1/2 and Erk1/2; β-actin was used as loading control. 
p53-/- MEFs (A) or Eµ-myc p53 null lymphoma cells (B) were treated with 10 μM 
piperlongumine for 6 h and then equal amounts of total proteins were subjected for 
immunoblotting analyses with designated antibodies. 
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Figure 17: NAC abolished activation of p38 and JNK induced by piperlongumine. 
Immunoblotting analyses of p-p38, p38, p-JNK, JNK, p-Erk1/2, Erk1/2 and cleaved 
caspase 3; β-actin was used as loading control. p53-/- MEFs were treated with 10 μM 
piperlongumine or co-treated with 3 mM NAC for 6 h and then equal amounts of total 
proteins were subjected for immunoblotting analyses with designated antibodies. 
 
I further investigated the relationship between ROS elevation and activation of 
p38 and JNK upon piperlongumine treatment by using specific inhibitors, 
SB202190 and SP600125, respectively. p53-/- MEFs were treated with 10 μM 
piperlongumine alone or with 25 μM SB202190, 20 μM SP600125 or 3 mM 
NAC for 1 h and the ROS level was measured with H2DCFDA fluorescent 
intensity detected by FACS. As shown in Figure 18, piperlongumine-induced 
ROS was abolished by NAC co-treatment, whereas co-treatment with 
SB202190 or SP600125 did not alter H2DCFDA fluorescent intensities in 
piperlongumine treated MEFs. However, co-treatment of SB202190 and 
SP600125 with piperlongumine reduced cell death caused by piperlongumine 
both in MEFs and lymphoma cells to some extent (Figure 19). Therefore, p38 
and JNK appeared to function as downstream targets of ROS accumulation 
inducing apoptosis upon piperlongumine treatment. 
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Figure 18: NAC but not p38/JNK inhibitors abolished piperlongumine-induced 
ROS elevation in p53-/- MEFs. p53-/- MEFs were treated with 10 μM piperlongumine 
alone or with 3 mM NAC, 25 μM SB202190 or 20 μM SP600125 for 1 h, and then 
stained with H2DCFDA. The mean H2DAFDA fluorescent intensity (representing 
cellular ROS level) was measured by FACS. Experiments were done in three different 
p53-/- MEFs, which were come from three different mice. Data are presented as mean 
± SD. 
 
 
Figure 19: Inhibitors of JNK/p38 partially block piperlongumine-induced cell 
death. Relative cell viability analyses by Guava ViaCount assay. (A) p53-/- MEFs were 
treated with 10 μM piperlongumine alone or with 25 μM SB202190 or 20 μM 
SP600125 for 6h, normalized to the native control of same group. (B) Eµ-myc p53 null 
lymphoma cells were treated with 25 μM piperlongumine alone or with 25 μM 
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SB202190 or 20 μM SP600125 for 6h, normalized to the native control of same group. 
Experiments were done in three independent p53-/- MEFs or Eµ-myc p53 null 
lymphoma cells. Data are presented as mean ± SD. 
 
Moreover, due to the increased Erk phosphorylation after piperlongumine 
treatment, I wondered whether inhibition of Erk could suppress the cell death 
induced by oxidative stress as p38/JNK inhibitors did. However, unlike p38 or 
JNK inhibitor, which could suppress tBHP-induced cell death (Figure 20), Erk 
inhibitor (PD98059) had no influence on cell death induced by tBHP (Figure 
20A) or H2O2 (Figure 20B). Taken together, these results indicated that 
piperlongumine induced apoptosis, which was mediated by ROS elevation via 
activation of p38 and JNK but not Erk. 
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Figure 20: Activation of JNK and p38 but not Erk1/2 contributes to oxidative 
stress induced cell death. Relative cell viability analyses by Guava ViaCount assay. 
(A) p53-/- MEFs were treated with 30 μM tBHP alone or co-treated with 25 μM 
SB202190, 20 μM SP600125 or 20 μM PD98059 for 6 h, normalized to the native 
control of same group. (B) p53-/- MEFs were treated with 1mM H2O2 alone or 
co-treated with 20 μM PD98059 for 24 h, normalized to the native control of same 
group. Experiments were done in three independent p53-/- MEFs. Data are presented 
as mean ± SD. 
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4.6 The piperlongumine-sensitive mutants attenuate 
piperlongumine-mediated NRF2 activation 
ROS accumulation is usually associated with a repression of the antioxidant 
defense system including the ROS detoxifying enzymes and their regulators 
(Nguyen et al., 2009). The transcription factor NRF2 has emerged as a master 
regulator of an intracellular antioxidant response through transcriptional 
activation of an array of antioxidant response element (ARE)-dependent genes 
such as glutathione S-transferase (GST), NAD(P)H oxidoreductase 1 (NQO1) 
and heme oxygenase 1 (HO-1) to regulate the physiological and 
pathophysiological outcomes of oxidant exposure (Al-Sawaf et al., 2015; 
Kensler et al., 2007). Consistent with the properties known for piperlongumine, 
I observed up-regulation of NRF2 protein levels following piperlongumine 
treatment (Figure 21). Of note, in MEFs or lymphoma cells harboring 
piperlongumine-sensitive mutants, the induction of NRF2 proteins seemed 
weaker than the empty control and other three p53 mutants following 
piperlongumine treatment.  
 
Figure 21: Piperlongumine increases up-regulation of NRF2 and p21 protein 
levels. Immunoblotting analyses of NRF2 and p21; β-actin was used as loading 
control. p53-/- MEFs (A) or Eµ-myc p53 null lymphoma cells (B) were treated with 10 
μM piperlongumine for 6 h and then equal amounts of total proteins were subjected 
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for immunoblotting analyses with designated antibodies. Experiments were done in 
three independent p53-/- MEFs or Eµ-myc p53 null lymphoma cells. 
 
Since NRF2 is a transcriptional factor, I wondered whether piperlongumine 
treatment also influence the transcription of NRF2 downstream genes, such as 
HO-1 and NQO1. To this end, MEFs treated with piperlongumine for 4 h or 8 h 
were analyzed for HO-1 and NQO1 expression levels by real time quantitative 
PCR (RQ-PCR) analysis. This analysis indicated that piperlongumine-sensitive 
mutants also led to an attenuated HO-1 and NQO1 induction upon 
piperlongumine treatment compared with the empty control and other three 
mutants (Figure 22). Hence, piperlongumine-sensitive mutants inhibited the 
induction and function of NRF2 in response to piperlongumine treatment due 
to a gain-of-function mechanism of mutant p53. 
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Figure 22: Piperlongumine-sensitive mutants repress the NRF2-dependent 
transcription of HO-1 and NQO1. RQ-PCR analysis of HO-1 and NQO1 in p53-/- 
MEFs treated with piperlongumine for 4 h or 8 h; expression in empty-MEFs (native) is 
normalized to 1. Experiments were done in three independent p53-/- MEFs. 
 
4.7 Keap1-independent regulation of NRF2 upon piperlongumine 
treatment 
The NRF2 signaling pathway is negatively controlled by Keap1. As shown in 
Figure 23, under normal conditions, Keap1 functions as a substrate adaptor for 
Cul3-based E3 ubiquitin ligase and constantly targets NRF2 for 
proteasome-dependent degradation to maintain it at very low level (Zhang and 
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Hannink, 2003; Zhang et al., 2004). Upon oxidative stress, modification of the 
cysteine residues on Keap1 imposes a conformational change resulting in 
diminished ubiquitination of NRF2 (McMahon et al., 2006; Tong et al., 2006). 
As a consequence, NRF2 protein level is increased, and the NRF2 signaling 
pathway is activated.  
 
Figure 23: The NRF2-Keap1 signaling pathway. In normal conditions, Keap1 
assembles into an E3 ubiquitin ligase complex with Cul3, Rbx1, and an 
ubiquitin-charged E2 enzyme and recruits Nrf2 for ubiquitination and proteosomal 
degradation. Binding affinity of Keap1 is much higher at the ETGE than at the DLG 
motif. Stress signals that induce Nrf2, by modifying Keap1 cysteine residues, trigger a 
change of protein conformation that loosens binding at the DLG and inhibits 
ubiquitination of lysine residues. Consequently, newly synthesized NRF2 proteins 
translocate into the nucleus and dimerize with members of the masculoaponeurotic 
fibrosarcoma (Maf) protein family that facilitates the binding of NRF2 to the AREs and 
drive the expression of NRF2 target genes such as HO-1, NQO1 and GST. E stands 
for ETGE motif, D stands for DLG motif.  
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Recently, piperlongumine has been proved to active NRF2 via thiol 
modification of Keap1 cysteine residues (Lee et al., 2015). Consistent with this 
finding, my previous data also demonstrated that piperlongumine induced 
activation of NRF2 in all cell settings. However, the amount of NRF2 was not 
equally increased upon piperlongumine treatment in the empty control and p53 
mutant cells, indicating that there might be some Keap1-independent 
mechanisms which contribute to various up-regulation of NRF2. 
 
4.7.1 Piperlongumine-sensitive mutants inhibit piperlongumine-induced 
p21 activation, which contributes to the cell death induced by 
piperlongumine 
As an alternative/plausible connection between p53 mutant and oxidative 
stress response, I considered p21, a well-known target of p53 regulating many 
cellular processes such as cell cycle arrest, cell differentiation, senescence, 
and apoptosis (Chen et al., 2009; O'Reilly, 2005). p21Cip1/WAF1 was reported to 
be associated with NRF2 signaling pathway in response to oxidative stress 
(Chen et al., 2009). p21 is up-regulated and activates NRF2 pathway in 
response to oxidative stress by competing with Keap1 for NRF2 binding, 
compromising the Keap1-dependent ubiquitination of NRF2 to confer 
protection against oxidative stress (Chen et al., 2009).  
We hypothesized that piperlongumine-sensitive mutants may repress p21 
expression induced by piperlongumine, contributing to the attenuation of 
piperlongumine-mediated activation of NRF2 and consequently leading to the 
severe cell death in cells harboring these p53 mutants. To test this hypothesis, 
I first did immunoblotting analysis to check the protein expression of p21 in 
response to piperlongumine treatment. As shown in Figure 21, the amount of 
p21 was less up-regulated by piperlongumine both in MEFs and lymphoma 
cells harboring piperlongumine-sensitive mutants than the empty control and 
Results 
77 
other p53 mutant cells, consistent with the tendency of NRF2 expression under 
same condition. NAC co-treatment with piperlongumine suppressed the 
expression of both NRF2 and p21 in MEFs (Figure 24). 
 
Figure 24: NAC suppresses piperlongumine-induced up-regulation of NRF2 and 
p21 protein levels. Immunoblotting analyses of NRF2 and p21; β-actin was used as 
loading control. p53-/- MEFs were treated with 10 μM piperlongumine alone or 
co-treated with 3 mM NAC for 6 h and then equal amounts of total proteins were 
subjected for immunoblotting analyses with designated antibodies. Experiments were 
done in three independent p53-/- MEFs. 
 
To evaluate whether piperlongumine-sensitive mutants also affect the mRNA 
expression of p21, MEFs were exposed to piperlongumine for 4 h or 8 h and 
then the transcriptional levels were measured by RQ-PCR. The result in Figure 
25 showed that the mRNA levels of p21 in MEFs with the empty control and 
p53R172H- p53G242S- and p53R279Q-mutant were increased more than 
piperlongumine-sensitive mutant cells following piperlongumine treatment. 
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Figure 25: Piperlongumine-sensitive mutants repress the mRNA level of p21 
induced by piperlongumine treatment. RQ-PCR analysis of p21 in p53-/- MEFs 
treated with piperlongumine for 4 h or 8 h; expression in empty-MEFs (native) is 
normalized to 1. Experiments were done in three independent p53-/- MEFs. 
 
To fully understand the correlation between p21 and NRF2, I knocked down 
p21 and NRF2 by transducing MEFs with shRNA against p21 and NRF2, 
respectively. In MEFs, shp21 and shNRF2 reduced the mRNA levels of p21 
and NRF2, respectively, both under native and piperlongumine-treated 
scenarios (Figure 26A). However, knocking-down p21 had no visible influence 
on NRF2 mRNA expression. Also, in response to piperlongumine treatment, 
knocking-down p21 and NRF2 attenuated the protein levels of p21 and NRF2, 
respectively (Figure 26B). Consistent with the finding that p21 stabilizes and 
activates NRF2 by protein-protein interaction, knocking-down p21 was 
associated with reduced NRF2 protein levels following piperlongumine 
treatment compared with the control (Figure 26B). Of note, knocking-down 
NRF2 did not affect the protein expression of p21 compared with the control. In 
addition to reducing NRF2 protein expression, p21 knock-down could also 
suppress the mRNA levels of HO-1 and NQO1 upon piperlongumine treatment, 
similar to the effect induced by knocking-down NRF2 (Figure 26C). However, 
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the induction of NRF2 protein and HO-1 and NQO1 mRNA following 
piperlongumine treatment was slightly stronger in p21 knocked down cells than 
in NRF2 knocked down cells (Figure 26B, C), implying that the attenuation of 
p21 may not be the sole mechanism responsible the cytotoxic activity of 
piperlongumine. Moreover, MEFs with knocked down p21 or NRF2 were more 
sensitive to piperlongumine treatment than the control cells (Figure 26D). 
Hence, p21 played a vital role in regulation of NRF2 upon piperlongumine 
treatment.  
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Figure 26: p21 up-regulates the protein levels of NRF2 in response to 
piperlongumine treatment. (A) RQ-PCR analyses of NRF2 and p21 in shControl, 
shNRF2 or shp21-transduced p53-/- MEFs. Cells were treated with 10 μM 
piperlongumine for 4 h. Expression in shControl-MEFs (native) is normalized to 1. (B) 
Immunoblotting of NRF2 and p21 in p53-/- MEFs infected with shNRF2- or 
shp21-retrovirus. Cells were treated with 10 μM piperlongumine for 4 h. β-actin was 
used as a loading control. (C) RQ-PCR analyses of HO-1 and NQO1 in shControl, 
shNRF2 or shp21-transduced p53-/- MEFs. Cells were treated with 10 μM 
piperlongumine for 4 h. Expression in shControl-MEFs (native) is normalized to 1. (D) 
Relative cell viability analyses of p53-/- MEFs infected with shControl-, shNRF2- or 
shp21-retrovirus by Guava ViaCount assay. Cells were treated with 10 μM 
piperlongumine for 6 h. Experiments were done in three independent p53-/- MEFs. 
Data are presented as mean ± SD. 
 
Since p21 is a well-known downstream target of wild-type p53, I aimed to 
dissect the gain-of-function properties of p53 mutants in regulation of p21 upon 
piperlongumine treatment. To this end, I performed a chromatin 
immunoprecipitation (ChIP) assay, using p53 antibody (Ab-1), which can 
recognize both wild-type p53 and all six p53 mutants, and performing RQ-PCR 
with primer specific for the promoter region of p21. I observed that, compare to 
native scenario, piperlongumine increased the amount of p53 proteins bound 
to the promoter of p21 in wild-type p53 and p53R172H, p53G242S and 
p53R279Q-mutant but not in piperlongumine-sensitive mutants (Figure 27A), 
suggesting that piperlongumine-sensitive mutants did not activate p21 
transcription upon piperlongumine treatment.  
To check whether piperlongumine activates other wild-type p53 downstream 
target gene, I designed primer specific for the promoter region of Mdm2 and 
performed RQ-PCR. Interestingly, the amount of p53 proteins bound to Mdm2 
promoter region was increased in all cell settings in response to 
piperlongumine treatment (Figure 27B). Taken together, 
piperlongumine-sensitive mutants may preferentially suppress the activation of 
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p21 in response to piperlongumine treatment, and further contribute to the 
reduction of activation and function of NRF2. 
 
Figure 27: Piperlongumine-sensitive mutants preferentially repress the 
activation of p21 in response to piperlongumine treatment. ChIP-qPCR analysis 
of p21 promoter (A) and Mdm2 promoter (B) with p53 antibody, as well as IgG 
(negative control). p53-/- MEFs were treated with 10 μM piperlongumine for 6 h.  
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4.7.2 Piperlongumine-sensitive mutants might inhibit cysteine 
modification of NRF2, which results in reduced nuclear translocation 
rates of NRF2 upon piperlongumine treatment 
The modification of cysteines in NRF2 is another possible mechanism for its 
regulation. Li et al. characterized a nuclear exporting signal (NES) in the Neh5 
transactivation domain which contains a reactive cysteine residue at position 
183 (Li et al., 2006). Mutating this residue (C183A) resulted in reduced 
translocation rates of NRF2 compared with wild-type upon tBHQ and H2O2 
treatment, while no significant effect was seen on Keap1 (Li et al., 2006). 
Under the conditions of oxidative stress, it is possible that sulfhydryl 
modification at Cys-183 prevents the binding of nuclear export protein 
chromosome region maintenance 1 (Crm1, also called Exportin 1, XPO1) to 
the NES motif in the Neh5 domain, resulting in NRF2 exporting accumulation 
(Li et al., 2006). Previous reports have revealed that NRF2 could physically 
interact with some p53 mutants but not wild-type p53 (Oren and Kotler, 2016). 
Consistently, all six p53 mutants but not wild-type p53 were found to interact 
with NRF2 especially in response to piperlongumine treatment by using 
immunoprecipitation assay (Figure 28). Piperlongumine-sensitive mutants may 
inhibit the cysteine modification of NRF2 at Cys-183 via protein-protein 
interaction especially upon piperlongumine treatment, and consequently 
facilitate the binding of Crm1 to Neh5 domain of NRF2, resulting in reduced 
nuclear translocation rates of NRF2. Nevertheless, this needs to be further 
investigated in the future. 
 
Figure 28: p53 mutants but not wild-type p53 interact with NRF2. 
Immunoprecipitation analyses with p53 antibody, as well as IgG (negative control) in 
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p53-/- MEFs. Immunoblotting of NRF2 and p53; β-actin was used as loading control. N 
stands for native, P stands for piperlongumine treatment (10 μM, 6 h). 
 
Interestingly, one recent report demonstrated that piperlongumine could 
directly bind to the Cys-528 of Crm1 and further inhibit the Crm1-mediated 
nuclear export (Niu et al., 2015). To test whether Crm1 inhibitor has similar 
effect like piperlongumine, MEFs were treated with two different dosages of 
KPT-330, a clinical inhibitor of Crm1. As shown in Figure 29A, KPT-330 could 
similarly induce cell death in a dose-dependent manner especially in MEFs 
harboring piperlongumine-sensitive mutants. Of note, KPT-330 induced cell 
death was abolished by co-incubation with NAC in MEFs (Figure 29B), 
implying that ROS accumulation may play a role in KPT-330 induced cell death. 
These data indicated that Crm1 may be a potential target for lymphomas 
harboring piperlongumine-sensitive mutants. In the future, it would be 
interesting to dissect the possibility of Crm1 as a potential target for 
lymphomas harboring piperlongumine-sensitive mutants. 
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Figure 29: Crm1 inhibitor induces cell death especially in p53-/- MEFs harboring 
piperlongumine-sensitive mutants. Relative cell viability analyses by Guava 
ViaCount assay. (A) p53-/- MEFs were treated with 5 μM or 20 μM KPT-330 for 24 h, 
normalized to the native control of same group. (B) p53-/- MEFs were treated with 20 
μM KPT-330 or co-treated with NAC for 24 h, normalized to the native control of same 
group. Experiments were done in three independent p53-/- MEFs. Data are presented 
as mean ± SD; ***, p < 0.005, p53R245Q, p53R246S and p53R270H-mutant vs the empty 
control. 
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5 DISCUSSION 
Tumor suppressor p53 is mutated in more than half of all human cancers, and 
many tumor-associated p53 mutant proteins gain new oncogenic functions, 
including promote tumor cell proliferation, anti-apoptosis, metastasis, energy 
metabolism (Freed-Pastor and Prives, 2012; Haupt et al., 2016; Liu et al., 
2014a). For example, tumor-associated p53 mutant stimulates the Warburg 
effect as a gain-of-function through promoting GLUT1 translocation to the 
plasma membrane, and inhibition of glycolysis in tumor cells greatly 
compromises p53 mutant gain-of-function in promoting tumorigenesis (Zhang 
et al., 2013). Therefore, exploring p53 mutant gain-of-function is a way to 
figure out the vulnerability of p53 mutant and serve as cancer therapeutics. 
In this study, I used the MEF and Eμ-myc lymphoma cell models in vitro to 
elucidate the metabolic vulnerabilities of p53 mutants and demonstrated that 
cells harboring p53R245Q, p53R246S and p53R270H-mutant were more sensitive to 
piperlongumine treatment than the empty control and p53R172H, p53G242S and 
p53R279Q-mutant. 
 
5.1 Alterations in energy metabolism in cells harboring p53 
mutants 
Cancer cells often have characteristic changes in metabolism, which provides 
enough cellular building blocks, such as nucleic acids, proteins and lipids, to 
maintain cell growth and proliferation. The best-characterized metabolic 
alteration in cancer cells is the Warburg effect, an energetically wasteful to 
glucose metabolism in which cancer cells utilize glucose to build other 
molecules via glycolysis instead of completely oxidizing them for maximal ATP 
generation (Berkers et al., 2013; Liu et al., 2014a). Another commonly 
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observed metabolic alteration in cancer is increased glutamine metabolism. In 
mammalian cells, glutamine is a major energy substrate to produce a-KG, 
which feeds into the TCA cycle. Glutamine can also be converted to citrate, 
which serves as a substrate for FAS in hypoxic cells (Fan et al., 2013). 
Furthermore, glutamine is an important energy source for the synthesis of 
GSH, an abundant antioxidant in cancer cells that is central for redox 
homeostasis and cell survival in response to oxidative stress (Diehn et al., 
2009). Fatty acids are also an important source of energy for cancer cells. In 
fact, FAO produces 2.5 times as much ATP per mole as oxidation of glucose, 
and some cancer cells express high levels of enzymes required for oxidation of 
fatty acids even when nutrients are abundant (Boroughs and DeBerardinis, 
2015).  
In the present study, I found the mRNA levels of some rate-limiting enzymes, 
such as GLUT3, GLS2 and CPT1C, which involve in the process of glucose 
uptake, glutaminolysis and FAO, respectively, were exhibited slightly higher in 
MEFs with piperlongumine-sensitive mutants than the empty control (data not 
shown). Unfortunately, MEFs with p53 mutants showed poor cytotoxic effect 
and minor difference compared with the empty control upon treatment of 
single-agent treatment via inhibition of energy-generating catabolic pathways 
by using 2-DG, BPTES or Etomoxir, respectively. (Figure 9). The reason could 
be because of two properties: cancer cells could use multiple catabolites to 
fuel ATP generation, maintain a redox balance, and support biosynthesis 
pathways; also cancer cells display great flexibility in utilization of catabolites 
depending on the environmental availability of nutrients. In addition, the 
metabolic feature obtained by OCR and ECAR measurement (Figure 8), to 
some extent, could partially explain the minor difference upon 2-DG, BPTES or 
Etomoxir treatment between these p53 mutants and the empty control. 
Therefore, targeting multiple metabolic pathways simultaneously through 
combination therapy might be a valid antitumor approach in future study. 
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5.2 p53 gain-of-function in response to oxidative stress 
As cancer cells have increased ROS generation due to metabolic 
abnormalities and oncogenic signaling, and possess increased intrinsic 
oxidative stress, it is conceivable that cancer cells would be more dependent 
on the antioxidant system and more vulnerable to further oxidative stress 
induced by exogenous ROS-generating agents or compounds that inhibit the 
antioxidant system in cells. Therefore, manipulating ROS levels by redox 
modulation is a way to selectively kill cancer cells without causing significant 
toxicity to normal cells. 
Compared to the empty control, although p53 mutants accelerated the growth 
rate in the p53-/- MEFs (Figure 7), I did not detect elevated basal levels of ROS 
in cells harboring p53 mutants (Figure 14, native), raising the possibility that 
under steady-state conditions, antioxidant system can counteract the elevation 
of ROS induced by p53 mutants. GSH plays critical role in cancer cell 
proliferation. Cancer cells with higher intracellular GSH level are resistant not 
only to apoptosis but also to chemotherapy (Estrela et al., 2006). It has been 
reported that piperlongumine could directly bind to and inhibit the antioxidant 
enzyme Glutathione S-Transferase Pi 1 (GSTP1), resulting in a decrease in 
GSH levels and subsequent promotion of cancer-selective cell death by 
increasing the ROS levels (Basak et al., 2016; Raj et al., 2011). Not 
surprisingly, piperlongumine induced severe cell death especially in cells 
containing piperlongumine-sensitive mutants compared with the empty control 
(Figure 12). Similarly, H2O2 or tBHP also exhibited strong cytotoxic effect in 
piperlongumine-sensitive mutant cells (Figure 10 and 11), indicating that 
piperlongumine-sensitive mutants might have gained new function in 
regulating pro-oxidant and antioxidant genes, which consequently made them 
more vulnerable to oxidative stress induced by exogenous ROS-generating 
agents.  
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However not all p53 mutants displayed similar response upon exogenous 
oxidative stress. Cells harboring p53R172H, p53G242S and p53R279Q-mutant were 
rather resistant to exogenous oxidative stress. Interestingly, p53R172H, p53G242S 
and p53R279Q-mutant are all conformational mutants, which cause a 
conformational change in the core domain. As mentioned before, these six 
hotspot residues can be classified into two categories: DNA-contact mutation 
(R248 and R273) and conformational mutation (R175, G245, R249 and R282). 
Accordingly, DNA-contact mutants, p53R245Q and p53R270H, were sensitive to 
oxidative stress, whereas conformational mutants, p53R172H, p53G242S and 
p53R279Q, were more likely resistant to oxidative stress (except p53R246S). In 
addition to the position of the mutation, the nature of the substitution may also 
influence the activity of the resulting mutant protein. For example, both 
p53R248Q and p53R248W-mutant are DNA-contact mutants, p53R248Q-mutant 
(humanized) knock-in mice showed an earlier onset of tumor formation with a 
significantly reduced lifespan compared with p53 null mice, whereas the 
humanized p53R248W-mutant knock-in mouse did not display reduced lifespan 
or earlier disease onset (Song et al., 2007).  
 
5.3 piperlongumine induces accumulation of ROS via p38 and JNK 
but not Erk 
As mentioned above, piperlongumine has been found to selectively kill many 
tumor cells but not normal cells by inducing ROS accumulation. Consistently, 
in this study the antioxidant NAC completely abolished 
piperlongumine-mediated ROS accumulation and effectively reduced the 
piperlongumine-induced cell death both in MEFs and lymphoma cells (Figure 
14 and 15), supporting the concept that ROS accumulation was the major 
mechanism contributing to the cytotoxicity of piperlongumine in cells harboring 
piperlongumine-sensitive mutants. 
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The signaling pathways participated in piperlongumine-induced cell death 
remain elusive. Different members of MAPK family, such as p38, JNK and Erk, 
can be activated by ROS, which leads to cell death or survival (Lee et al., 2005; 
Liu et al., 2014b; Repicky et al., 2009; Samuelsen et al., 2007; Xiong et al., 
2015). Hence, differences in the duration and magnitude of the oxidative stress 
might be related to the activation of these kinases and thus determine cell 
death or survival. For example, it has been reported that ROS accumulation 
induced by piperlongumine can activate the p38- and JNK-mediated 
downstream signaling pathways, which contribute to apoptosis or autophagy 
(Liu et al., 2013a; Xiong et al., 2015). Erk activation plays an important role in 
H2O2-induced glioma cell death (Lee et al., 2005). Herein, the activation of 
both p38 and JNK were noticed upon piperlongumine treatment especially in 
cells harboring piperlongumumine-sensitive mutants (Figure 16). Antioxidant 
NAC blocked the activation of p38 and JNK (Figure 17), and inhibitors of p38 
and JNK partially blocked piperlongumine-induced cell death (Figure 19) but 
not ROS induction (Figure 18). However, although piperlongumine 
up-regulated phosphorylation of Erk in all cell settings (Figure 16 and 17), 
inhibitor of Erk (PD98059) could not rescue the cell death induced by tBHP or 
H2O2 (Figure 20). The similar outcome would be achieved by co-treatment of 
PD98059 with piperlongumine as well. Therefore, p38 and JNK rather than Erk 
dependent mechanisms were involved in the piperlongumine-induced 
apoptosis in these two cell types. 
 
5.4 NRF2 regulation upon oxidative stress 
ROS levels are tightly controlled by the NRF2/Keap1 pathway (Jaramillo and 
Zhang, 2013). As described above, the transcription factor NRF2 has emerged 
as a master regulator of intracellular antioxidant response through 
transcriptional activation of an array of genes, which protect cells from toxic 
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and carcinogenic signals. Under normal conditions, NRF2 is constantly 
ubiquitinated through Keap1 in the cytoplasm. Following exposure to ROS, 
Keap1 is inactivated and NRF2 is stabilized. Consequently, NRF2 translocates 
into the nucleus, where it activates transcription of antioxidant and detoxifying 
genes by binding to the AREs in their regulatory regions (Figure 23). Recent 
studies have also shown that various human cancers exhibit gain-of-function 
mutations in NRF2 and loss-of-function in Keap1 and Cul3 which lead to the 
increased activity of NRF2 in cancers and further confer a great advantage to 
cancer for survival against oxidative stress, chemotherapeutic agents and 
radiotherapy (Kim et al., 2010; Ooi et al., 2013; Singh et al., 2010; Wang et al., 
2008; Zhang et al., 2010). Therefore, a better understanding of the role of 
NRF2 signaling in cancer would be important for cancer prevention and 
treatment through targeting NRF2. 
 
5.4.1 piperlongumine-sensitive mutants attenuate piperlongumine- 
induced NRF2 activation 
In the present study, the activation of NRF2 and NRF2 target genes (HO-1 and 
NQO1) induced by piperlongumine were attenuated in cells harboring 
piperlongumine-sensitive mutants (Figure 21, 22 and 24). Consistently, a 
previous study has also shown that p53R248Q and p53R273H-mutant, which 
equivalent to p53R245Q and p53R270H-mutant in mouse, attenuate the activation 
and function of NRF2 upon Diethylmaleate (DEM, a glutathione-depleting 
compound) treatment (Kalo et al., 2012). However, they demonstrated that 
p53R273H-mutant enhances oxidative burden and increases cell survival in 
p53-/- cells (Kalo et al., 2012). The discrepancy in treatment outcome may be 
due to the following two reasons: 
(1) The antioxidant capacity of the cell is different. It is believed that cells with 
more aggressive oncogenic features would possess higher ROS levels 
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(Klaunig and Kamendulis, 2004). For example, normal cells can tolerate a 
certain level of exogenous oxidative stress due to reserved antioxidant 
capacity (Trachootham et al., 2009). However, owing to metabolic 
abnormalities and oncogenic signaling tumor cells experience an increased 
ROS generation, which may trigger a redox adaptation response of tumor cells, 
leading to an up-regulation of antioxidant capacity and a shift of redox 
dynamics to maintain the ROS levels below the toxic threshold (Trachootham 
et al., 2009). As such, tumor cells would be more dependent on the antioxidant 
system and more vulnerable to further oxidative stress induced by exogenous 
ROS-generating agents. Since ectopic expression of c-myc is responsible for 
inducing malignant changes, c-myc highly expressed p53-dificient cells, used 
in the present study, may be more vulnerable to further oxidative stress. 
(2) The magnitude of oxidative stress induced by exogenous agents is different. 
Exogenous agents that increase ROS generation or decrease antioxidant 
capacity will result in an overall increase in the level of ROS. The increased 
ROS might function as a double-edge sword. A moderate increase of ROS 
may promote cell proliferation and survival. However, if the increase of ROS 
reaches a certain level, ROS may overwhelm the antioxidant capacity of the 
cell and trigger cell death. Although piperlongumine and DEM are both 
glutathione-depleting compound, piperlongumine has been reported to 
selectlively kill many solid and hematologic tumor cells. It is possible that 
piperlongumine induces acute increase of ROS while DEM stimulates 
moderate increase of ROS. 
 
5.4.2 Keap1-independent regulation of NRF2 
As mentioned above, the activity of NRF2 is primarily regulated via its 
interaction with Keap1, which directs NRF2 for proteasomal degradation. It has 
been reported that piperlongumine-induced activation of NRF2 is mediated by 
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thiol modification of cysteine residues present in Keap1 (Lee et al., 2015). In 
addition to Keap1-dependent mechanism of regulation, many reports has 
revealed alternative mechanisms of NRF2 regulation, including 
phosphorylation of NRF2 by various protein kinases (such as PKC, PI3K/Akt, 
p38, JNK), interaction with other protein partners (p21, caveolin-1) and 
epigenetic factors (mi-144, -28 and -200a, and promoter methylation) (Bryan et 
al., 2013).  
Piperlongumine-sensitve mutants suppressed piperlongumine-induced 
activation of p21 and thus contributed to the attenuation of 
piperlongumine-mediated NRF2 activation (Figure 30B). The protein and 
mRNA levels of p21 were both increased in the empty control and p53 mutant 
cells upon piperlongumine treatment (Figure 21, 24, 25). However, ChIP with 
anti-p53 antibody showed that, upon piperlongumine treatment, 
piperlongumine-sensitive mutants slightly suppressed p21 transcription, 
whereas the other three p53 mutants promoted the activation of p21 like 
wild-type p53 (Figure 27A). These data indicated that piperlongumine induced 
activation of p21 through both p53-dependent and p53-independent 
mechanisms. But, the detailed p53-independent mechanism still needs to be 
dissected. Interestingly, one latest report demonstrated that p53R249S 
(equivalent to p53R246S in mouse) but not wild-type p53 binds to and stabilizes 
c-myc in the nucleus, consequently leading to the activation of c-myc (Liao et 
al., 2017), which raises the possibility that p53R245Q and p53R273H might also 
interact with c-myc and stabilize c-myc like p53R246S. C-myc is a nuclear 
transcriptional factor critical for cell proliferation and tumorigenesis (Gordan et 
al., 2007). The activation of c-myc results in down-regulation of p21 (Gui et al., 
2004), so the reason that piperlongumine induced p53-independent activation 
of p21 in these two cell types, which c-myc was ectopically expressed, may be 
because piperlongumine decreased the expression of c-myc and further 
contributed to the activation of p21. However, piperlongumine-sensitive 
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mutants might bind to c-myc and rescue the suppression of c-myc caused by 
piperlongumine, thereby resulting in the attenuation of p21. It would be worth 
to investigate the expression of c-myc upon piperlongumine treatment and the 
binding of c-myc to these six p53 mutants in the future. 
In addition to the role of p21 in NRF2 regulation, sulfhydryl modification of 
NRF2 at Cys-183 in the Neh5 domain might be another Keap1-independent 
mechanistic way for NRF2 regulation in response to piperlongumine treatment. 
Previous studies have addressed a bipartite nuclear localization signal (NLS) 
and two NES motif in NRF2 (Jain et al., 2005; Li et al., 2006) (Figure 30A). 
Under the unstimulated state, the combined nuclear exporting forces of NES 
motif in Neh5 domain (referred to as NESNeh5 in the following) and NES motif in 
Neh1 domain (referred to as NESNeh1 in the following) can effectively 
counterbalance the nuclear localization force of the NLS motif and provide 
sufficient nuclear export driving force to hold NRF2 in the cytoplasm (Li et al., 
2006). In the nucleus, Crm1 binds to the NESNeh5 of NRF2 and causes NRF2 
nuclear export. As a result, NRF2 displays a predominantly cytosolic 
distribution. Under the conditions of oxidative stress, the activity of 
redox-sensitive NESNeh5 can be disabled by sulfhydryl modification of the 
Cys-183 residue embedded in the NESNeh5, but the redox-insensitive NESNeh1 
and NLS motif remain functional, resulting in the prevailed driving force 
mediated by the NLS motif, which triggers the nuclear translocation of NRF2 
(Li et al., 2006). Cysteine modification in NESNeh5 could also suppress the 
binding of Crm1 to NRF2 in the nucleus. Together, piperlongumine would 
increase the nuclear translocation rates of NRF2. Although all six p53 mutants 
could interact with NRF2 (Figure 28), it would be possible that 
piperlongumine-sensitve mutants might inhibit the cysteine modification of 
NRF2 upon piperlongumine treatment via protein-protein interaction. Thus, 
functional NESNeh5 would not only combine with NESNeh1 to counteract the 
nuclear importing mediated by NLS motif but also bind to Crm1 (Figure 30C), 
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leading to the increased nuclear exporting rates of NRF2 in 
piperlongumine-sensitive mutant cells. 
 
Figure 30: Keap1-independent regulation of NRF2. (A) Domain structures of NRF2. 
The N-terminal region of NRF2 is designated Neh2 domain, which contains two motifs, 
DLG and ETGE, responsible for the interaction with Keap1. Neh1 domain is a 
basic-region leucine zipper motif for DNA binding and dimerization with Maf. Neh3 
and Neh4 and Neh5 domains are important for the transactivation activity of NRF2 
(Mitsuishi et al., 2012). (B) NRF2 is stabilized in response to p21 up-regulation. p21 
associates with the DLG motif on NRF2, thereby competing with Keap1 and resulting 
in an increase in nuclear NRF2. However p53R245Q (p53R246S or p53R270H) could 
suppress the up-regulation of p21, leading to the destabilization of NRF2. (C) 
Piperlongumine induces sulfhydryl modification of NRF2 at Cys-183 in the Neh5 
domain, contributing to the increased the nuclear translocation rates of NRF2. 
However, p53R245Q (p53R246S or p53R270H) binds to NRF2, which may suppress the 
cysteine modification of NRF2 in Neh5 domain, and facilitate the binding of Crm1 to 
Neh5 domain of NRF2, resulting in reduced nuclear translocation rates of NRF2. 
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5.5 Restoration of functional status to mutant p53 by 
piperlongumine 
It has been well studied that stabilization of mutant p53 in tumors is crucial for 
its oncogenic activities, while depletion of mutant p53 attenuates malignant 
properties of tumor cells (Freed-Pastor and Prives, 2012; Gurpinar and 
Vousden, 2015; Muller and Vousden, 2013). Therefore, reactivation of mutant 
p53 into functional form and depletion of mutant p53 are considered as 
improved and efficient anticancer therapies.  
The anticancer effects of piperlongumine have been reported to may partially 
stem from oxidative stress-induced modification of the p53 protein, leading to 
the restoring of wild-type p53 and decreasing of intrinsic p53 mutant both in 
HT29 and SW620 cell lines harboring p53R273H-mutant (Basak et al., 2016). 
Interestingly, the immunoprecipitation results also exhibited that 
piperlongumine up-regulated wild-type p53 and down-regulated all six hotspot 
mutants compared with untreated condition (Figure 28, immunoblotting of p53). 
In addition, NAC co-incubation with piperlongumine restored 
piperlongumine-decreased expression of p53 mutants (data not shown), 
implying that piperlongumine caused the modification of p53 mutants and 
resulted in the decreasing of p53 mutants. However, owing to Ab-1 (p53 
antibody) recognizes both wild-type and mutant p53, it is uncertain whether 
piperlongumine could cause a concomitant reactivation of wild-type p53 in p53 
mutant cells. It would be interesting to further investigate the potential property 
of piperlongumine in reactivation of wild-type p53 in lymphomas harboring p53 
mutants. 
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5.6 Cytotoxic effect of KPT-330 in piperlongumine-sensitive mutant 
cells 
Crm1, the main nuclear export protein, transports cargo proteins containing 
leucine-rich NES out of the nucleus (Fornerod et al., 1997; Fukuda et al., 1997; 
Gerace, 1995). Through nuclear pore complex Crm1 exports proteins such as 
inhibitor of NF-kB (IkB), BRCA1, p53, p73, Rb and FOXO from the nucleus to 
regulate cell cycle, cell proliferation and apoptosis (Abdul Razak et al., 2016; 
Abraham and Holyoake, 2013; Kau et al., 2004; Turner et al., 2009). 
Overexpression of Crm1 has been reported in multiple solid and hematologic 
malignancies, and correlates with poor prognosis of several tumor types, 
including acute myeloid leukemia (AML), mantle-cell lymphoma (MCL), glioma, 
cervical and pancreatic cancer (Abdul Razak et al., 2016; Etchin et al., 2016; 
Huang et al., 2009; Shen et al., 2009). Therefore, inhibition of Crm1 is being 
considered as a promising target for cancer therapy. 
KPT-330 is a clinical agent that has been shown to bind to cysteine-528 in the 
NES-binding groove of Crm1 to inhibit its nuclear export function, and it is 
currently in advanced clinical development phase for treatment of solid and 
hematologic malignancies (Etchin et al., 2016; Nair et al., 2017). It is probable 
that Crm1 inhibitors potentially induce massive cell death in cells harboring 
piperlongumine-sensitive mutants due to piperlongumine is believed to inhibit 
Crm1-mediated nuclear export (Niu et al., 2015). Consistently and interestingly, 
KPT-330 had strong activity against MEFs harboring piperlongumine-sensitive 
mutants while sparing the empty control and other three p53 mutants (Figure 
29A). Noteworthy, KPT-330 for the first time may induce ROS accumulation 
since NAC suppressed the cell death caused by KPT-330 (Figure 29B). 
However, it is possible that other mechanisms other than ROS accumulation 
might be involved in this process since Crm1 mediates nuclear export of ~200 
leucine-rich NES-containing proteins. For instance, Crm1 is involved in the 
activation of oncogenic pathways, at least in part through activated nuclear 
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export of eukaryotic initiation factor 4e (eIF4e), the sole transporter of 
guanine-capped mRNAs, including c-myc, cyclin D1 and Mdm2 (Tan et al., 
2014). Increased nuclear export of oncogenic transcripts to the cytosol 
promotes synthesis of cognate oncoproteins, which drive cell survival and 
proliferation. Therefore, inhibition of Crm1 by KPT-330 would restrict them to 
the nucleus and prevent the translation of them, resulting in anticancer 
activities. In the future, it would be interesting to dissect the possibility of Crm1 
as a potential target for lymphomas harboring piperlongumine-sensitive 
mutants. 
 
5.7 Future perspectives 
5.7.1 Can Crm1 be a potential target for lymphomas harboring 
piperlongumine-sensitive mutants? 
As increased Crm1 expression has been linked to poor prognosis in both solid 
tumors and leukemias, Crm1 inhibition has emerged as a cancer therapeutic 
strategy. KPT-330 is a selective inhibitor of Crm1 and currently enters clinical 
trials for treatment of hematologic and solid malignancies, with promising 
results. Therefore, it would be interesting to investigate the strong activity of 
KPT-330 against lymphomas harboring piperlongumine-sensitive mutants both 
in vitro and in vivo. In addition, due to the heterogeneity of tumors, multiple 
mutations or epigenetic alterations may co-exist. Thus, combinatorial tumor 
therapies using multiple drugs (for instance piperlongumine combines with 
KPT-330) may be necessary to achieve better treatment outcome. 
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5.7.2 Can piperlongumine (or KPT-330) achieve prominent treatment 
outcome in vivo? 
By using in vitro cell models we have addressed that exogenous oxidative 
stress could cause significant cell death in cells harboring 
piperlongumine-sensitive mutants. However, the in vivo situation is by far more 
complex, such as heterotypic cell-cell interactions and inhomogeneous drug 
delivery that could not covered by in vitro analyses. Therefore, to address the 
potential anticancer activity of piperlongumine (or KPT-330) in lymphomas 
harboring p53 mutants, it will be interesting to investigate genetically 
compatible transplant lymphomas in vivo. p53 null Eμ-myc lymphoma cells 
harboring piperlongumine-sensitive mutant (for instance p53R270H) or p53R172H 
as well as the empty control for comparison are going to transplanted into 
normal, immunocompetent recipient mice, where they form systemic 
lymphomas indistinguishable from the primary transgenic host they are initially 
derived from. When a peripheral lymphadenopathy becomes palpable, mice 
harboring a comparable tumor burden will be treated with the piperlongumine 
(or KPT-330) by intraperitoneal injection for 2 weeks, and the change of tumor 
volume during this period will be recorded. Also the lymphomas can be 
analyzed by using a nitroblue tetrazolium (NBT) reduction assay where ROS 
reaction with NBT results in a dark blue precipitate. 
 
5.7.3 Can piperlongumine restore wild-type p53 activity in p53 mutant 
cells? 
As discussed above, p53 mutant proteins are highly expressed in many 
cancers and the reduction of p53 mutant proteins is associated with the 
attenuation of malignant properties of tumor cells, making them extremely 
attractive targets for therapy. Strategies have focused on destabilization of 
mutant p53, or reactivation of wild-type function in the mutant p53 protein. In 
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the present study, in response to piperlongumine treatment we found that 
piperlongumine caused the stabilization of p53 in p53-/- MEFs harboring 
wild-type p53, and the reduction of all six hotspot p53 mutants in MEFs 
harboring these p53 mutants as well. Due to the increasing of p53 proteins 
induced by piperlongumine in MEFs harboring wild-type p53, it would be 
probable that piperlongumine also induces reactivation of wild-type p53 activity 
in p53 mutant MEFs. We will verify the reactivation of p53 mutant by 
immnoblotting using the specific antibody, which only recognizes wild-type p53. 
Moreover, although p53R172H, p53G242S and p53R279Q-mutant resistant to 
piperlongumine treatment, it is probable to acquire better treatment outcome 
by piperlongumine combined with other drugs if piperlongumine could be 
proved to restore the expression of wild-type p53 in these p53 mutant cells. 
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6 CONCLUSIONS  
In this thesis, we investigated the metabolic vulnerabilities of p53 mutant in 
vitro using p53-deficient MEFs and Eµ-myc lymphoma cells, which were stably 
introduced with six hotspot mutants of p53. Piperlongumine, a natural product 
isolated from long pepper, induced severe cell death in cells harboring 
p53R245Q, p53R246S and p53R270H-mutant (piperlongumine-sensitive mutants). A 
subsequent study showed that piperlongumine-induced cell death was 
mediated by ROS accumulation through activation of p38 and JNK. The use of 
antioxidant NAC or p38/JNK inhibitors could completely or partially suppress 
piperlongumine-induced cell death. The mechanisms underlying the cell death 
induced by piperlongumine in cells harboring piperlongumine-sensitive 
mutants could partially because these three mutants inhibited 
piperlongumine-induced activation of p21 and consequently caused the 
attenuation of piperlongumine-induced NRF2 up-regulation, leading to the 
reduction of antioxidant capacity in cells harboring these mutants. Moreover, 
KPT-330, a clinical inhibitor of Crm1, also caused strong activity against cells 
harboring piperlongumine-sensitive mutants, indicating Crm1 as potential 
target for lymphomas harboring piperlongumine-sensitive mutants. Taken 
together, the present work newly provides insights into therapeutic implications 
for lymphomas harboring p53 mutants. 
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ABBREVIATIONS 
ACC Acetyl CoA carboxylase 
ACLY ATP citrate lyase 
AIF Apoptosis-inducing factor 
ALDH4 Aldehyde dehydrogenase 4 
AMPK AMP-activated protein kinase 
APC Adenomatous polyposis coli 
APL Acute promyelocytic leukemia 
ARE Antioxidant response element 
ATP Adenosine triphosphate 
BRCA1 Breast cancer type 1 susceptibility protein 
CPT1C Carnitine Palmitoyltransferase 1C 
DNA Deoxyribonucleic acid 
EMT Epithelial-mesenchymal transition 
eIF4e Eukaryotic initiation factor 4e 
FADH2 Reduced flavin adenine dinucleotide 
 
FAO Fatty acid oxidation 
FAS Fatty acid synthesis 
FASN Fatty acid synthase 
GLUT Glucose transporter 
GLS2 Glutaminase 2 
GAMT Ganidinoacetate methyltransferase 
G6PDH Glucose-6-phosphate dehydrogenase 
GPX1 Glutathione Peroxidase 1 
GSH Glutathione 
GST glutathione S-transferase 
HDAC6 Histone deacetylase 6 
H2DCFDA 2',7'-dichlorodihydrofluorescein diacetate 
HO-1 Heme oxygenase 1 
H2O2 Hydrogen peroxide 
Hsp Heat shock protein 
Keap1 Kelch-like ECH-associated protein 1 
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α-KG α-ketoglutarate 
MAPK Mitogen-activated protein kinase 
MCT1 Monocarboxylate transporter 1 
ME Malic enzyme 
MEF Mouse embryonic fibroblast 
mTOR Mammalian target of rapamycin 
NAC N-acetyl-L-cysteine 
NADH Reduced nicotinamide adenine dinucleotide 
NADPH Reduced nicotinamide adenine dinucleotide phosphate 
NF-Y Nuclear factor Y 
NQO1 NAD(P)H oxidoreductase 1 
NRF2 NF-E2-related factor 2 
RB Retinoblastoma-associated protein 
ROS Reactive oxygen species  
OXPHOS Oxidative phosphorylation 
p53R2 p53-controlled ribonucleotide reductase 
PDHA1 Pyruvate dehydrogenase E1 
PDK2 Pyruvate dehydrogenase kinase 2 
PFK1 Phosphofructokinase 1 
PGM Phosphoglycerate mutase 
PI Propidium iodide 
PIG Tumor protein p53 inducible protein 
Pin1 Prolyl isomerase 
PKM2 Pyruvate kinase M2 
PML Promyelocytic leukemia 
PPP Pentose phosphate pathway 
SCO2 Synthesis of cytochrome c oxidase 2 
SREBP1 Sterol regulatory element-binding protein 1 
tBHP tert-Butyl hydroperoxide 
 
TCA Tricarboxylic acid 
TIGAR TP53-induced glycolysis and apoptosis regulator 
VDR Vitamin D receptor 
XPO1 Exportin 1 
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